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ABSTRACT 
The immunostimulatory ability of oligonucleotides containing CpG motif (CpG-ODN), agonists 
of TLR9, can be harnessed to promote antitumor immunity by their application at the tumor site to 
stimulate local activation of innate immunity; however, this is not always true for lung tumor 
where the immunosuppressive microenvironment, crucial to avoid tissue damage by inflammatory 
response to the continuous exposition to inhaled particles, limits the power of immunotherapy. 
Thus, the tumor microenvironment is a critical factor for successful use of these 
immunotherapeutics, and strategies to shift a tumor-supporting milieu to a host-friendly one might 
lead to improved anti-tumor activity of CpG-ODN. Since bronchial and bronchoalveolar tumors 
are accessible via the endobronchial space, inhalation of aerosolized immunotherapeutic agents 
might represent a convenient and simple approach to shape a tumor microenvironment more 
favorable to induce an immune response against lung primary cancer and/or metastases.  
Aim of this thesis is the evaluation of strategies to improve the antitumor activity of aerosolized 
TLR9 agonist in the lung. The thesis is divided in three tasks: 1) the evaluation of aerosol delivery 
CpG-ODN combined with Poly(I:C), a TLR3 agonist able to convert tumor-supporting 
macrophages to tumoricidal effectors, in the treatment of B16 melanoma lung metastases in 
C57BL/6 mice. 2) the investigation of the mechanism by which the two combined agonists could 
induce the activation of effector cells population. 3) the exploration of strategies to improve the 
therapeutic efficacy of TLR9/TLR3 agonists by including in the inhalant either an antibody 
directed to both Ly6G and Ly6C markers, to locally deplete myeloid-derived suppressive cells 
(MDSC), or IFNα, to directly activate innate immune cells in the lung. 
Aerosolization of CpG-ODN with Poly(I:C) into the bronchoalveolar space reduced the presence 
of M2-associated arginase- and IL-10-secreting macrophages in tumor-bearing lungs and 
increased the anti-tumor activity of aerosolized CpG-ODN alone against B16 lung metastases 
without apparent signs of toxicity or injury of the bronchial-bronchiolar structures and alveolar 
walls. Moreover, CpG-ODN/Poly(I:C) aerosol combined with dacarbazine, a therapeutic agent 
used in patients with inoperable metastatic melanoma able to exert immunostimulatory effects, led 
to a significant increase in anti-tumor activity as compared to treatments with aerosolized CpG-
ODN/Poly(I:C) or dacarbazine alone. This effect was related to an enhanced recruitment and 
cytotoxic activity of tumor-infiltrating NK cells in the lung. Our in vitro and in vivo experiments 
to elucidate the mechanism of NK cells activation by TLR9/TLR3 stimulation revealed that the 
two agonists were able to directly induce IFN-γ secretion by NK cells, but the stimulation of their 
cytotoxic activity required the presence of alveolar macrophages. Interestingly, our experiments 
demonstrated that, reciprocally, NK cells were able to influence macrophages polarization, since 
alveolar macrophages incubated with activated NK cells from the lungs of melanoma metastases-
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bearing mice that were given aerosolized TLR9/TLR3 agonists, up-regulated M1- and down-
regulated M2-related genes. 
Addition of nebulized anti-MDSC antibody RB6-8C5 to aerosolized CpG-ODN/Poly(I:C) resulted 
in reduced mRNA levels of immunosuppressive molecules (IL10, Arg-1 and Nos2), increased 
activation of resident NK cells and improved treatment outcome, with a significant reduction in 
established B16 melanoma lung metastases, compared to treatment with CpG-ODN/Poly(I:C) 
alone. Likewise, addition of aerosolized IFN-α led to increased mRNA levels of pro-inflammatory 
cytokines (IL15 and IFN-γ) in the lung and recruitment of highly activated NK cells, with no 
evident signs of toxicity and with a significantly improved anti-tumor effect, as compared with 
aerosolized CpG-ODN/Poly(I:C). Combining both IFN-α and RB6-8C5 with CpG-ODN/Poly(I:C) 
did not produce additive effects. 
In conclusion, the results of this thesis indicate that the pulmonary route is a feasible and non-
invasive strategy to deliver immunodulatory molecules, including antibodies and cytokines, to 
reprogram the lung microenvironment shaping it more favorable to foster immune destruction of 
tumors. 
 
GRAPHICAL ABSTRACT 
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INTRODUCTION 
1. TOLL-LIKE RECEPTORS (TLRs) 
The human body is provided with a system capable of defending against external assault to which 
we are daily exposed, that may generate serious damage to our body. The cells and molecules 
responsible of this protection compose the so-called immune system. The immune system has 
developed during evolution to defend the body from any form of chemical insult, traumatic or 
infective to their integrity. 
In mammals the defense against foreign and tumor cells is based on early response, mediated by 
innate immunity, and on late responses, mediated by adaptative immunity. 
The innate immune activation and discrimination between what is proper organism (self) and what 
is not part of it (non-self) is mediated by pattern-recognition receptors (PRRs), which recognize 
common molecular structures in groups of microbes similar between them. The PRRs include the 
Mannose receptors (MR), the family members of the Toll-like receptors (TLRs), the NOD-like 
receptors (NLRs) and the nucleotide-binding oligomerization domains proteins. 
The PRRs generally recognize pathogen-associated molecular patterns (PAMPs), microbial 
components highly conserved, essential for the survival of micro-organisms, that include nucleic 
acids peptides and microbial cell wall components (eg. LPS peptidoglycan and lipoproteins). There 
are also other PRRs that are capable of recognizing also endogenous stress signals defined danger-
associated molecular patterns (DAMPs). 
The best known PRR family is the Toll-like receptors (TLRs). The TLR genes have been conserved 
in evolution; In fact, homologous receptors have been identified as those shown in mammals also 
in Caenorhabditis elegans and Drosophila melanogaster. The first member of this family called 
Toll was first identified in the Drosophila melanogaster, which represents a model for the study of 
the innate immune defense (Hoffmann J,2003, Nature). 
This receptor appears to be responsible for the embryonic development of the Drosophila dorsal-
ventral and seems to play a fundamental role in the adult life of insect as an important factor in the 
antifungal protection. In fact, mutations in the Toll receptor lead to occurrence of fungal infections 
affecting the survival of insect (Hoffmann J,2003, Nature). 
The discovery of immune function of Toll in Drosophila led to the search for homologous receptors 
in mammals and the first receptor identified was the TLR4 (Medzhitov R,1997, Nature). 
In mammals there are 13 different TLR genes: 10 genes in human (TLR1-10) and 12 genes in mice 
(TLR 1-9 and 11-13). Some of them are homologous (Albiger B, 2007, J Intern Med; Akira S, 
2004, Nat Rev Immunol). The TLRs are considered sensors for microbial infections and other 
"danger signals" and represent an important point of connection between the innate and the 
adaptive response. 
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1.1 MOLECULAR STRUCTURE AND CELLULAR DISTRIBUTION OF 
TLRS 
The TLR receptors belong to the superfamily of interleukin-1 receptor (IL-1R) (Medzhitov R,1997, 
Nature; Takeda K, 2003, Annu Rev Immunol) and are integral membrane type I glycoproteins. The 
intracellular domain, responsible for the signal transmission, is homologous to the receptor for 
interleukin-1 (IL-1R), and for this reason it takes the name of Toll/IL-1R domain or IRR (Akira S, 
2006, Microbiol Immunol; Akira S, 2001, Nat Immunol). The extracellular domain differs from IL-
1R to the presence of 19-25 of leucine-rich motifs repeated in tandem (LRR) each consisting of 24-
29 amino acids forming a β sheet and α helix connected to each other so as to create a loop. The 
extracellular portion of the IL-1R is instead characterized by a structure consisting of 
immunoglobulin domains (figure 1). 
 
 
 
Figure 1. 
Schematic representation of the superfamily of Toll-IL-1R. The IL-1 receptor (IL-1R) 
and the Toll-like receptors (TLR) have a common pathway of signal transmission due 
homologous cytoplasmic domain called TIR, where they bind adapter molecules. The 
extracellular domain instead is differentiated by the presence in the IL-1 receptor of 
an immunoglobulin structure and in the TLRs of region with repeated in tandem 
leucine-rich motifs (LRR) responsible for the recognition of PAMPs. (From Albiger 
B, 2007, J Intern Med) 
 
The LRR motif is responsible for the recognition of the specific PAMPs of bacteria, parasites, 
fungi and viruses (Albiger B, 2007, J Intern Med; Akira S, 2006, Microbiol Immunol). 
The genes coding for TLRs are located on different chromosomes: those coding for the TLR1 and 
TLR6 map the human chromosome 4p14, TLR2 and TLR3 the chromosome 4q31.3-q35, TLR4 the 
chromosome 9q32-q33, TLR5 the chromosome 1q33.3-q42, TLR7 and TLR8 the chromosome 
Xp22 and TLR9 the chromosome 3p.21.3. Each of them is able to recognize a particular group of 
PAMPs. 
The members of TLRs family are expressed predominantly and variably, depending on the specific 
receptor, on immune cells, such as macrophages, dendritic cells (DC), monocytes, B cells, mast 
cells, natural killer cells, neutrophils, eosinophils and T cells (Akira S, 2006, Microbiol Immunol). 
Some studies have shown that these receptors may also be expressed on non-hematopoietic-derived 
cells, mainly epithelial cells (Parker LC, 2007, Clin Exp Immunol) localized at the level of 
potential entry sites of pathogens, such as the skin, the respiratory tract, intestinal and urogenital 
tracts. The TLRs 2, 3, 4, 5, 9 are expressed in epithelial bronchial and gastrointestinal tracts. The 
TLR3 appears to play a fundamental role on cefalorachidiana barrier and lastly different TLRs, 
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such as TLR4 and TLR9, are expressed in the gut with a different distribution in various intestinal 
compartments. 
The specificity of different TLRs is partially influenced by their structure and by their cellular 
localization, which can be intracellular or at the cell surface. In general, most of the TLRs (TLRs as 
1, 2, 4, 5, 6 and 10) are expressed on the cell surface, while others (such as TLRs 3, 7, 8, 9) are 
located in intracellular compartments, such as endosomes. The ligands of these last TLRs (mainly 
nucleic acids) therefore require an internalization inside the cell to bind to the receptors. Their 
expression also is not static but finely and rapidly modulated in response to various stimuli, such as 
contact with pathogenic microorganisms, various inflammatory cytokines and environmental stress 
(Akira S, 2006, Microbiol Immunol). 
 
1.2 MAIN LIGANDS OF TLRS 
The transduction of the signal through TLRs requires the dimerization of TLR proteins on the cell 
membrane, which sometimes involves homodimerization of same TLRs and other times 
heterodimerization of two different TLR proteins. The repertoire of the specificity of the TLR 
system is therefore extends to the ability of TLR to heterodimerize with each other (figure 2). 
The TLR2 recognizes various molecules, such as bacterial lipopeptides, molecules localized at the 
level of the cellular membrane of yeast, molecules of parasites and viral proteins, the acid 
lipoteichoic acid (LTA) and peptidoglycan of Gram-positive bacteria and finally some glycolipids. 
The wide range of ligands recognized by TLR2 is due to the fact that this receptor may 
heterodimerize with two other TLRs, the TLR1 and TLR6. The heterodimer TLR1 / TLR2 
recognizes triacetilate lipoproteins, while the heterodimer TLR2 / TLR6 recognizes diacetilate 
peptidoglycan and lipoproteins (Takeuchi O, 2002, J immunol; Lien E,1999, J Biol Chem). 
The TLR5 detects the conserved domain present in the flagellin monomers, the major structural 
protein of the flagella of both Gram-negative and Gram-positive (Hayashi, 2001, Nature). The 
TLR9 is a receptor capable of recognizing nucleic acids with not methylated CpG-rich motifs, 
characteristic of bacterial and viral organism prokaryotes (Bauer S, 2001, PNAS). Also the TLR3, 
TLR7 and TLR8 recognize nucleic acids, but unlike the TLR9, bind RNA sequences in double or 
single stranded. In particular, the TLR3 is designated to recognition of the double helix viral RNA, 
while the single-stranded RNA interacts with the TLR7 and TLR8 (Alexopoulou L, 2001, Nature; 
Heil F, 2004, Science). 
The specificity of the TLRs are also affected by the binding capacity of various accessory 
molecules. For example, TLR4 is able to recognize also numerous ligands structurally different 
from each other, such as the lipopolysaccharide (LPS), viral proteins and some heat-shock proteins, 
thanks to the recruitment of other molecules, such as CD14, MD2 and CD11b/CD18. The different 
combinations of accessory molecules in the TLR complexes can therefore serve to increase the 
spectrum of microbial products able to induce innate responses. Finally, as regards the TLR 10, it is 
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not yet aware of the specific ligand, although recently it has been demonstrated its ability to form 
homodimers or heterodimers with TLR1 and TLR2. 
Figure 2. 
Examples of microbial products able to activate the various TLRs: lipopolysaccharide (LPS to TLR4), unmethylated 
oligonucleotides (CpG to TLR9) or double-stranded RNA molecules (poly (I: C) for TLR3). (from McInturff JM, 2005, J 
Invest Dermatol) 
 
Were also identified endogenous ligands recognized by TLR, mainly represented by molecules 
produced under stress or cell damage. A potential sign of stress is the increase of the expression of 
heat shock proteins (Hsps), molecules involved in the assembly of the proteins and their 
translocation in the different cellular compartments. It is noted for example that the Hsp60 protein, 
both in bacteria and in mammals, once released from necrotic cells is able to activate the TLR4. 
Finally, also molecules generally released during an inflammatory response, such as various 
components of the extracellular matrix, can interact with family members of TLRs (Akira S, 2001, 
Nat Immunol). 
 
1.3 THE PATHWAY OF TLRs SIGNALING 
The dimerization of TLR induced by ligand allows the binding of cytoplasmic adaptors to the 
cytosolic tails through homotypic interactions of TIR domains present both on TLR receptors and 
on protein adapters. The activation of the cascade signal results in the induction of the transcription 
of genes involved in the activation of an inflammatory response and host antimicrobial response 
mechanisms. In particular, TLRs transmit the signal through four possible cytoplasmic adapters: 
MYD88 (myeloid differentiation factor 88), TIRAP (Tyr-associated protein), also called Mal 
(Myd88-like adapter), TRIF (Tir-domain-containing adapter inducing INFβ), also known as 
TICAM-1 (Tir-domain containing molecule1) and TRAM (adapters TRIF-related molecules), also 
called TICAM-2. 
The various TLRs use different combinations of the adapters and this explains the different effects 
obtained following activation by the various ligands. 
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In particular, there are two possible signaling pathways: the way MyD88 independent and the way 
MyD88-dependent. The first pathway leads to the production of type I interferons, (IFN α or β). 
The second route use for signaling the adapter MyD88 to activate the NF-kB nuclear factor, JUN 
kinase (JNK) and p38, with the consequent production of proinflammatory cytokines, such as 
TNFα, IL-12 and IL-1, and the induction of typical mechanisms of innate immunity (figure 3) 
(Iwasaki A,2004, Nat Immunol). 
All TLRs (except TLR3) and all members of the IL-1R family, recruit MyD88 at the level of the 
TIR portion of the receptor. The pathway independent from MyD88 involves TLR3, while TLR4 
use both MyD88 dependent and independent pathway. 
Figure 3. 
Pathways of TLRs signaling. The TLR, after the binding with their ligand, causing a signaling cascade leading the 
activation of proinflammatory responses. The route of transmission of the signal can be MyD88-dependent and MyD88-
independent. The first way leads the production of proinflammatory cytokines, while the second to interferons of type I. 
(from Takeda K, 2003, Annu Rev Immunol) 
 
The Activation of TLRs also induces maturation of dendritic cells (DCs), resulting in secretion of 
cytokines and chemokines and expression of costimulatory surface molecules such as CD40, CD80 
and CD86. In particular, the activation of TLRs 3,4,7, and 9 involves the activation of T 
lymphocytes CD8+ CTL with high production of IFNγ and other cytokines important in the activity 
of the anticancer immune system (Peng G, 2005, Science). 
The TLR can also regulate cell death. Stimulation of these PRR can cause the activation of the 
PI3K-AKT pathway that promotes cell survival and also appears to be associated with increased 
expression of anti-apoptotic proteins such as Bcl2-A1 (Bcl2-related protein A1) and other members 
the Bcl-2 family. 
Depending on the type of infection, different immune cell subsets produce different cytokines and 
chemokines in order to limit the spread of infection. In general, it tends to affirm that the response 
induced by an extracellular pathogen is characterized by the production of pro-inflammatory 
 11 
 
cytokines such as TNFa and IL-12, while in case of infection by an intracellular microbe, the 
response is characterized by the production of interferons type I (Krieg AM, 2006, Nat Rev Drug 
Discov). TLRs play a crucial role in the connection between the two types of immunity, therefore 
the use of TLR to promote the immune surveillance mediated by IFNγ and T lymphocytes, is a 
possible immunotherapeutics strategy against cancer. 
 
2. CHARACTERISTICS OF TOLL-LIKE RECEPTOR 9 AND TLR3 
The TLR9 and TLR3 are members of the TLR family on which many studies have focused in 
recent years. Their expression and effects resulting from their activation, make these PRRs a 
promising target for immunotherapy. 
TLR9 is able to recognize specific sequences of nucleic acids, characterized by non-methylated CG 
dinucleotides (CpG motifs) very represented in bacterial and viral DNA. The genomes of bacteria 
and some viruses generally contain a CpG dinucleotide every 16 bases, while in vertebrates the 
frequency is greatly reduced and the CpG motifs are almost always methylated (Krieg A.M, 2007, 
Proc Am Thorac Soc). The activation of TLR3 is through the recognition of viral double-stranded 
RNA (Cheng YS, 2010, Cancer Biol Ther) which prime the homodimerization, but not induce 
conformational changes (Liu L, 2008, Science). 
For therapeutic applications the TLR9 is generally activated through the use of synthetic 
oligonucleotides (ODN) that contain one or more CpG motifs (Krieg A.M, 1995, Nature), while the 
signaling of TLR3 is activated by Polyinosinic-polycytidylic acid (PolyI:C), a synthetic analog of 
double-stranded RNA (Cheng YS, 2010, Cancer Biol Ther). 
 
2.1 STRUCTURE OF TLR9 AND TLR3 
Currently it is still unknown the molecular structure of TLR9. There are in fact little information on 
structure of TLRs that have high clinical importance, such as TLR7, TLR8 and TLR9; on the 
contrary there are more detailed knowledge about the structure of other family members of TLRs 
such as TLR1/TLR2, TLR3 and TLR4, of which the binding mechanisms with the respective 
ligand are known. Crystallography data of ectodomain (ECD) of the TLR3 indicate that the 
enriched leucine region (LRRs) are responsible for the recognition of pathogen structures. 
Recently, starting from the crystallographic structure of ECD of human TLR3, it was generated a 
homologue model of TLR9. With this model it is seen that, similarly to what happens for TLR3, 
also in the TLR9 there are two positively charged sites and there are other residues conserved 
positively loads on the N-terminal of EDC which would seem involved in the recognition of CpG 
motifs. These sites maintain a similarity of structure with the N-terminal binding site of TLR3 
(Kubarenko A.V, 2010, Protein Sci). Of course all of these modeling studies should be validated 
with the corresponding crystallographic structure. 
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2.2 EXPRESSION AND LOCALIZATION OF TLR9 AND TLR3 
TLR9 is predominantly expressed in immune system cells. In humans it is expressed exclusively in 
B cells (Bernasconi NL, 2003, Blood) and plasmacytoid dendritic cells (pDCs) (Kadowaki N, 2001, 
J Exp Med), a type of specialized dendritic cells responsible for most of the production of type I 
IFN in response to viral or intracellular pathogens (Iwasaki A,2004, Nat Immunol). Some studies 
have also shown the functional expression of TLR9 on activated human neutrophils and on non-
hematopoietic cells, such as epithelial cells of the respiratory and the gastrointestinal tract (Parker 
LC, 2007, Clin Exp Immunol; Hopkins PA, 2005, Clin Exp Immunol). 
The expression profile of TLRs differs among different species and this does not allow to have 
accurately predictive animal models of the effects of the activation of TLR9. For example, in the 
mouse TLR9 is also expressed in monocytes, macrophages and myeloid dendritic cells, thus 
generating amplified effects than those observed in human following its activation. 
In non-active immune cells, TLR9 is located in the endoplasmic reticulum (ER). The DNA 
recognition takes place in endolysosomes (Leifer CA, 2006, J Biol Chem). Some studies in the past 
had shown that TLR9, during the translocation from the ER to the early endosomes, do not cross 
the Golgi complex; on the contrary recent studies have shown that the TLR9 cross the Golgi 
complex before reaching the early endosomes and that export from the Golgi apparatus is a 
required step for optimal transduction of the activation signal (Chockalingam,2009, Immunol Cell 
Biol). 
In contrast, in epithelial cells the TLR9 is expressed on the cell surface, on the basolateral or on the 
apical membrane and the signal transduction seems to vary according to the different location. In 
fact, the basolateral stimulation of TLR9 leads to activation of the NFκB pathway, whereas 
stimulation of the apical TLR9 prevents the activation of NFκB, promoting the production of NFκB 
inhibitory protein, IκBα (inhibitory protein I kappa B-alpha). 
TLR3 expression, such as TLR9, is limited to specific cell types. Both in human and mice, TLR3 is 
located on the ER or early endosome in macrophages, myeloid dendritic cell (DCs), NK cells and 
on the cell surface of non-immune cells like, fibroblast, alvelolar epithelial cells and intestinal 
epithelial cells (Cheng YS, 2010, Cancer Biol Ther). 
 
2.3 TLR9 AND TLR3 ACTIVATION AND SIGNAL TRASDUCTION 
Stimulation of TLR3 and TLR9 by dsRNA or CpG-DNA occurs only after the pathogens were 
endocytated or phagocyted or after the virus has infected the cell. Once the microbial DNA is 
found in the endosomal or lysosomal compartment, inside the cell, it will be recognized by TLR9 
and TLR3. Essential for the recognition of CpG-DNA by TLR9 is the acidification of the 
endosomes and lysosomes. Some drugs, such as china chlorine (CQ) and the bafilomycin A1 
(ATP-dependent inhibitor of acidification of endosomes), in fact stop the activation of the signal 
cascade induced by TLR9, preventing acidification of the endosomal compartments. 
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It was demonstrated that the recruitment of MyD88 factor immediately after the activation of TLR9 
determines the appearance of a truncated form of TLR9 into the endolysosome, indicating that the 
truncated receptor, rather than the full-length form, is functional (Ewald S, 2008, Nature). 
The activation of TLR9 does not involve the mediator TIRAP / MAL. The intracellular signaling of 
TLR9 is mediated by MyD88, which are recruited to TIR domain and activate the pathway IRAK1-
IRAK6-TAK1. 
The cascade of the TLR9 signal involve mitogen-activated protein kinase, such as p38, JNK and 
ERK and the pathway of NF-kB-inducing kinase (NIK) -IKK-IκB and culminates with the 
activation of specific transcription factors, such as NF-kB, AP-1 (activating protein-1), C/EBP 
(CCAAT/enhancer binding protein) and protein CREB (cAMP-responsive element-binding 
protein), which directly induce gene expression of cytokines and chemokines. Some studies have 
shown that treatment with a drug called wortmannin (WM) leads to a reduction in the number and 
size of the endosomes containing CpG-DNA and TLR9. These studies suggest that the enzyme 
PI3K (phosphatidylinositol 3-kinase), which is the target of the WM, could be involved in vesicular 
trafficking of CpG-DNA (Ishii KJ, 2002, J Exp Med). In particular, the PI3K and its second 
messengers could play an important role at various stages of activation cell mediated by the 
binding CpG-DNA / TLR9 (figure 4). 
Figure 4. 
Summary scheme of the intracellular signaling 
mediated by TLR9/CpG DNA. PI3K of class III 
allow internalization of the ODNs in the 
endosomal vesicles containing TLR9. The same 
enzyme, together EEA1 antigen, mediates the 
maturation of endosomes containing CpG-DNA 
and TLR9 and trafficking inside the cells. The 
signal cascade begins with the recruitment of 
MyD88 at level of the TIR domain, which 
activates the complex IRAK-TRAF6-TAK1, 
which in turn determines the activation of JNK 
½, p38 and IKK complex, causing the up-
regulation of the transcription factors NF-kB 
and AP-1. (from Klinman DM, 2004, Nat rev. 
Immunol)  
 
 
 
After binding to its ligand, the TLR3 recruits TRIF that binds the IKK-1 adapter which activates 
the transcription factors interferon regulatory factor 3 (IRF3), nuclear factor kappaB (NFkB) and 
Activator Protein 1 (AP1). This signaling induce the production of type I IFN and the production of 
inflammatory cytokines, causing the activation of NK cells and CD8+ T lymphocytes and 
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promoting the development and maturation of dendritic cells. The difference in the two pathways 
of TLR3 and TLR9 is that TLR9 activates mainly NFkB with the consequent production of pro-
inflammatory cytokines at an early stage, while the agonists of TLR3 induce the activation of 
NFkB and IRF3 at late stage with the main effect to induce the production of IFN type I (Akira S, 
2006, Microbiol Immunol). 
 
3. SYNTHETIC AGONISTS OF TLR9 (CpG-ODN) AND TLR3 (Poly 
I:C) AND THEIR USE IN CANCER THERAPY 
TLR9 recognizes nucleotide sequences enriched in not methylated CpG motifs characteristic of the 
bacterial and viral genome, where the frequency of unmethylated CG dinuleotides is greater than 
the frequency founded in the vertebrate genome. 
Since their binding to TLR9 stimulate cascade of events that activates both innate and adaptive 
immune system, in the course of the years it appeared of interest to develop synthetic 
oligonucleotides CpG-rich capable of inducing optimal activation of TLR9, by modifications of 
nucleotide bases, of the skeleton or of secondary and tertiary structure. These sequences were 
produced with the aim to generate molecules able to stimulate an immune response versus the 
tumor cells in immunotherapeutic approaches. 
Poly(I:C) is a synthetic analog of double-stranded RNA developed to improve antiviral response 
(Baron S, 1969, PNAS), able to activate both the innate and adaptive immune system by binding to 
TLR3. Different types of modified Poly(I:C) have been developed during the years to limit the 
toxicity. Several researchers have worked to modify the molecular structure of poly(I:C), 
generating a Poly(I:C) highly stable with increased specificity versus the TLR3, resulted very 
efficacious agent in immunotherapy against tumor (Carter WA, 1985, J Biol Response Mod, 
Comparative; Carter WA, 1985, J Biol Response, Preclinical; Hubbell, 1987, J Biol Response 
Mod; Bucur N, 1998, Neurol Med Chir; Akazawa, 2007, PNAS; Chin Al, 2010, Cancer Res; 
Harrison SD, 1990, J Biol Response Mod; Shime H, 2012, PNAS; Levy HB, 1975, J Infect Dis; 
Stephen EL, 1977, Science; Levy HB, 1978, J Infect Dis; Olsen GA, 1978, J Infect Dis; Machida H, 
1982, Microbiol Immunol). 
 
3.1 PRECLINICAL STUDIES ON MICE 
Some of the most innovative studies concerning the therapeutic use of CpG-ODN and Poly(I:C) 
have been conducted in animal models (Iwasaki A, 2004, Nature; Carter WA, 1985, J Biol 
Response Mod, Comparative; Carter WA, 1985, J Biol Response, Preclinical; Hubbell, 1987, J 
Biol Response Mod; Bucur N, 1998, Neurol Med Chir; Akazawa, 2007, PNAS; Chin AL, 2010, 
Cancer Res; Harrison SD, 1990, J Biol Response Mod; Shime H, 2012, PNAS). Thanks to studies 
on TLR9 knockout mice, it was clearly shown that TLR9 is the receptor of CpG-ODN and proved 
that the CpG-ODN exerts its effects through the activation of this receptor. 
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The agonists of TLR9 and TLR3 were tested in different animal models of cancer and have shown 
moderate success in inducing the reduction of the tumor when administered alone or in 
combination with other cancer treatments, such as radiation or monoclonal antibodies (Krieg AM, 
2004, Curr Oncol Rep; Carter WA, 1985, J Biol Response Mod, Comparative; Carter WA, 1985, J 
Biol Response, Preclinical; Hubbell, 1987, J Biol Response Mod; Bucur N, 1998, Neurol Med 
Chir; Levy HB, 1975, J Infect Dis; Levy HB, 1978 J Infect Dis; Stephen EL, 1977, Science; Olsen 
GA, 1978, J Infect Dis; Machida H, 1982, Microbiol Immunol). 
 
3.1.1 Monotherapy 
The antitumor efficacy of CpG-ODN and Poly(I:C) depends on the type of tumor. The mechanism 
of action of these agents depends on various factors, including the susceptibility of the tumor to 
immune effector cells (NK or T cells) and the expression of TLR9 and TLR3 on the tumor cells. 
Moreover, the treatment with CpG-ODN alone has been shown effective in some tumors only if 
administered peritumorally or intratumorally, it, but ineffective, if systemically administered 
(Heckelsmiller K, 2002. J Immunol; Kawarada Y, 2001, J Immunol). 
In several studies Poly(I:C) showed antitumor activity, mostly since its ability to induce a change in 
the microenvironment from pro-tumoral to anticancer (Shime H, 2012, PNAS; Shime H, 2014, J 
Innate Immun), to activate the immune system (Talmadge JE, 1985, Cancer Res; Ebihara T, 2010, 
J Exp Med; Akazawa, 2007, PNAS) and to have direct effects on tumor (Cheng YS, 2010, Cancer 
Biol Ther). 
 
3.1.2 Association with therapeutic agents 
The therapeutic effects of CpG-ODN are higher when given in combination with other therapeutic 
agents (Krieg AM, 2004, Curr Oncol Rep). In animal models of cancer, treatment with CpG-ODN 
in combination with fluorouracil, with inhibitors of topoisomerase I (Balsari A, 2004, Eur J 
Cancer), with cyclophosphamide (Weigel BJ, 2003, Clin Cancer Res), or with paclitaxel resulted in 
an increased survival, compared to treatment with CpG-ODN alone. 
The oligonucleotide was combined effectively even with cetuximab and cisplatin in ovarian cancer 
model (Sommariva M, 2011, Cancer Res; De Cecco L, 2013, PloS One) and with DCs based 
immunotherapy in colon carcinoma C26 animal model (Bourquin C, 2006, Int J Cancer). 
 
3.2 CpG-ODN AND POLY(I:C) IN ANTITUMORAL CLINICAL TRIAL 
The promising results showing antitumor efficacy of TLR9 agonist and of Poly(I:C) when used as a 
single agent in mice studies have prompted the development of several clinical trials.  
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3.2.1 CpG-ODN in Clinical Trial 
3.2.1.1 Non-Hodgkin Lymphomas 
Since Non-Hodgkin's lymphomas (NHL) usually well respond to treatment with immunomodulants 
(Liu Q, 2006, J Clin Oncol), the efficacy of monotherapy with CpG-ODN (Agatolimod) was tested 
in a clinical trial of phase I conducted in NHL patients, previously treated with standard therapy. 
Patients were divided into 7 cohorts (3 patients for each cohort) and received three i.v. infusions 
weekly of Agatolimod from one of six established doses (0.01, 0.04, 0.08, 0.16, 0.32, 0.64 mg/kg). 
By the second day after the treatment, these patients showed an increase in the absolute number of 
NK cells and an increased NK cell activity, compared to levels before treatment although After 42 
days of treatment no clinical response was observed. This clinical study therefore showed that 
Agatolimod can be safely administered to patients previously treated for NHL, and that treatment 
with this drug produces immunomodulatory effects (Link BK, 2006, J Immunother). 
A Phase I study was conducted in patients with relapsed B cells NHL to evaluate the tolerability, 
toxicity and antitumor activity of the combination of agatolimod with rituximab (a monoclonal 
antibody directed to the surface antigen CD20 widely expressed by B cells). It has been shown that 
the CpG-ODN increases the expression of the target of rituximab in various types of lymphomas. 
Agatolimod was administered by two routes (i.v. and s.c). in combination with standard doses of 
rituximab. Patients were divided into 3 groups; all received rituximab i.v. at a dose of 375mg/m
2
 
for week, for 4 weeks, followed by weekly administration of agatolimod s.c. for the cohort 1 (0.01, 
0.04, 0.08, 0.16 mg/kg), or Agatolimod i.v. for cohort 2 (0.04, 0.16, 0.32, 0.48 mg/kg) for 4 weeks. 
The third group received Agatolimod s.c. every week for 20 weeks, at 0.24 mg/kg dose. Among 
patients of Cohort 1, 21% achieved a complete response (CR) or partial response (PR). Similar 
results were observed in 11% of patients in the cohort 2. In cohort 3, however, the 50% of patients 
(6 of 12) achieved a PR or CR, while in 25% of cases a stable disease was maintained. In this 
cohort, it was observed an increase in the levels of cytokines and chemokines. From this study it 
was concluded that agatolimod can be administered to patients with NHL in combination with 
rituximab, either subcutaneously or intravenously, without increasing of toxicity related to 
infusions of rituximab alone (Leonard JP, 2007, Clin Cancer Res). 
 
3.2.1.2 Renal Cell Carcinoma 
In a multicenter phase I study the effects of the weekly s.c. administration of agatolimod (dose 
range 0.08-0.81 mg/kg) for 24 weeks was evaluated in patients with advanced renal cell carcinoma 
(Thompson JA, 2004, J Clin Oncol). 31 patients were recruited, 18 males and 13 females aged 
between 35 and 79 years. One patient had a durable partial response (8 months), 9 patients 
maintained stable disease, while 17 had disease progression despite treatment with Agatolimod. No 
side effects were observed and Agatolimod was well tolerated up to the weekly dose of 0.54 mg / 
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kg. There were biological responses, including increased levels of IP10 and OAS (oligoadenylate 
synthetase), consistent with the mechanism of action of the agonists of TLR9. 
 
3.2.1.3 Melanoma 
The main limitations of immunotherapy for melanoma and other cancers are the immune evasion 
mechanisms developed by the tumor, which make the host tolerant to the tumor antigens. It was 
noted that melanoma inhibits the maturation of APC, thus preventing the activation of T cells and 
the immunological response (Kirkwood JM, 2008, J Clin Oncol). The CpG-ODN was used in 
different protocols of treatment of melanoma, both as a single agent or in combination with other 
drugs. 
A multicenter phase II clinical trial conducted to evaluate the effects of TLR9 chronic activation by 
weekly administrations s.c. of agatolimod in melanoma patients showed a moderate but consistent 
increase in CD86+ pDCs percentage in the blood and their activation, as demonstrated by the high 
levels of IFN type I. It was also observed a reduction in the number of CD56+/CD16+ NK cells in 
the blood of patients receiving agatolimod, probably as a result of recruitment at the tissue level. In 
two patients was confirmed PR, while 3 have maintained stable disease. This study therefore 
showed that the therapy based on TLR9 agonists in patients with melanoma may stimulate an 
innate immune response and led to the identification of biomarkers that may be associated with 
tumor regression induced by the activation of TLR9 (Pashenkov M, 2006, J Clin Oncol). 
Phase II study was conducted in 184 patients divided randomly into 4 different cohorts: 1) 
treatment with 10 mg of agatolimod, 2) treatment with 40 mg of agatolimod, 3) the combination of 
40 mg of agatolimod with DTIC (dacarbazine), 4) DTIC alone. Agatolimod was administered s.c. 
every week, while DTIC was administered every 21 days i.v. at a dose of 850 mg/m
2
. Preliminary 
response in 92 patients was evaluated, showing a PR in 4 subjects who received the combination, 
while in the single DTIC group there were only 2 PR. This study concluded that the combination 
CCID and agatolimod could be more effective than treatment with DTIC alone in patients with 
metastatic melanoma (Wagner S, 2005, J Clin Oncol). 
The CpG-ODN has also been used in immunotherapy protocol for melanoma as adjuvant. A pilot 
study was designed to investigate the immunogenicity of NY-ESO1 peptide in combination with 
157-165V agatolimod and Montanide ISA 720 (another adjuvant) in 8 patients at stage III / IV with 
melanoma expressing NY-ESO1 (Fourcade J, 2008, J Immunother). The patients were divided into 
the following groups: 1) immunization with agatolimod and Montanide (3 patients); 2) 
immunization with Montanide and NY-ESO1 157-165V peptide (2 patients); 3) immunization with 
Montanide, agatolimod and NY-ESO1 157-165V peptide. The results of these studies show that 
vaccination with the peptide in combination with the two adjuvants promotes the expansion of 
CD8+ T cells specific for NY-ESO1 even in patients with advanced cancer. 
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Finally, a phase I study was conducted to evaluate the effects on cytokines serum levels, safety and 
clinical activity of agatolimod administered to lesions in patients with metastatic melanoma or with 
BCC (basal cell carcinoma) (Hofmann MA, 2008, J Immunother). Agatolimod was administered at 
doses up to 10 mg, every 14 days in 5 patients with BCC and in 5 melanoma patients with 
cutaneous or subcutaneous metastases. Both groups showed a local tumor regression and increased 
levels of IL-6 in all patients, increased IFNγ levels in 8 patients out of 10, increased IL-12 p40 
levels in 7 out of 10 patients and an increase of TNF-α in 7 out of 10 patients.  
A Phase Ib study has recently opened to evaluate the association of CMP-001, CpG-A 
oligodeoxynucleotide (ODN) formulated within a virus-like particle, with pembrolizumab (anti-
PD-1 antibody) to facilitate activation of the innate immune response within a tumor that will 
enhance response to anti-PD-1/L1 therapy. The trial enroll patients with advanced melanoma and 
present with either progressive disease, or stable disease after at least 12 weeks of pembrolizumab 
therapy (Clinical trial information: NCT02680184).  
 
3.2.2 POLY(I:C) in clinical trial 
The efficacy of Ampligen (PolyI:C) is being tested in combination with different types of agents, 
such as celecoxib, IFNα and Hiltonol in various clinical trials performed in different types of 
cancers, such as breast cancer, colon rectal cancer and cancer of reproductive tract (Galluzzi L, 
2012 Oncoimmunology). 
Numerous preclinical studies to test the antitumor activity of Hiltonol (Poly(ICLC)) have shown 
good results, leading to the development of various phase I and II clinical trial to evaluate the 
safety and activity of Poly(ICLC) in a plethora of cancers: hematological malignancies (Levine As, 
1978, Cancer Treat Rep; Lampkin B, 1985, Cancer Res; Giantonio BJ, 2001, Invest New drugs; 
Durie BG, 1985 J Biol Response Mod), melanoma (Hawkins MJ, 1985 J Biol Response Mod), 
ovarian cancer (Rettenmaier MA, 1986, Gynecol Oncol), renal cancer (Giantonio BJ, 2001, Invest 
New drugs; Droller MJ, 1987, J Urol) and other cancers (Krown SE, 1985, J Biol Response Mod; 
Stevenson HC, 1985, J Biol Response Mod; Ewel CH, 1992, Cancer Res; Morse AM, 2011, Clin 
Cancer Res). 
 
3.2.2.1 Hematological Cancer 
A phase I-II trials with 19 patients with different tumors and 6 patients with acute leukemia were 
performed. Patients, Poly(I:C) administered at a dose of 0.5-27 mg/m
2
, showed a significant 
increase of interferon production that resulted directly proportional to the dose administered. 
Adverse reactions were fever, nausea, hypotension in relation to the dose used of TLR3 agonist 
(Levine As, 1978, Cancer Treat Rep). A similar effect was observed also in another phase II 
clinical trial on patients with acute lymphoblastic leukemia and not acute lymphoblastic, where an 
increase of interferon in 50% of patients was detected (Lampkin B, 1985, Cancer Res). 
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Seven patients with refractory multiple myeloma in a phase II trial were treated with Poly(I:C). In 
one patient a partial response (PR) was observed and in 3 patients an objective response was 
observed. Even in these patients was detected an increase of interferon (Giantonio BJ, 2001, Invest 
New drugs). 
 
3.2.2.2 Melanoma 
In a phase I-II study, 16 patients with metastatic melanoma were treated with Poly(I:C). In this 
study no anti-tumor responses were observed, but there was an increase in the concentration of 
interferon in the serum of patients eight hours aftert treatment with TLR3 agonist (Hawkins MJ, 
1985 J Biol Response Mod). 
 
3.2.2.3 Association with immunomodulators and chemotherapy 
25 patients with different types of tumor were enrolled in a phase IB study, where the association 
of TLR3 agonists with interleukin 2 was evaluated. A slight toxicity and the absence of objective 
tumor response was observed, but all patients treated with this combination showed an increase in 
NK cells activity (Ewel CH, 1992, Cancer Res). 
Morse et al. has conduct a study to evaluate the combination of poly(I:C) with CDX-1307, a 
vaccine composed of human chorionic gonadotropin beta chain fused with MR-specific 
monoclonal antibody in epithelial cancer patients. The combination of TLR3 agonists with the 
vaccine induced a high immune response and clinical benefit represented by an increase in the 
duration of stable disease (Morse AM, 2011, Clin Cancer Res). 
Two other Phase II studies evaluated the association of TLR3 agonists with chemotherapy. In the 
first, survival increase was observed in patients with glioblastoma treated with Poly(I:C) in 
combination with temozolomide (Rosenfeld MR, 2010, Neuro Oncol) while in the second a 
significant increase in disease-free survival and a reduction in the incidence of metastases in 
patients with breast cancer treated with radiotherapy in combination with TLR3 agonist (Laplanche 
A, 2000, Breast Cancer Res Treat). 
Overall, these studies have shown that the use of TLR3 agonist in patients is safe and is able to 
induce an activation of the immune system. 
 
4. IMMUNE MICROENVIRONMENT IN THE LUNG AND 
APPROACHES FOR ITS MODULATION 
4.1 IMMUNE MICROENVIRONMENT IN THE LUNG 
The airways every day filter considerable amount of air and this determines a continuous contact 
with solid particles, allergens and microbes. The continuous exposure to external environment 
induces the formation of a pulmonary immunosuppressive microenvironment, governed by several 
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types of cells such as dendritic cells, lung-resident macrophages, and regulatory T cells. In the 
absence of pathogens or inflammatory diseases, these cells ensure to eliminate the above mentioned 
elements while maintaining the lung environment in a state of immunosuppression (De Heer HJ, 
2004, J Exp Med; Hintzen G, 2006, J Immunol; Lambrecht BN, 2012, Annu Rev Immunol; Lo B, 
2008, J Immunol; Strickland DH, 2006, J Exp Med). 
 
4.4.1 Dendritic cells resident in the lung: 
Lung resident DCs derive from Hematopoietic Stem Cell in the bone marrow that undergo 
maturation becoming Pre-DC; these cells reach the lung through blood and differentiate into 
conventional or plasmacytoid DCs. The cytokine Flt3L and GM-CSF appear to be essential 
elements for all stages of dendritic cells differentiation (Liu K, 2009, Science; Greter M, 2012, 
Immunity). 
DCs are mainly divided in conventional DCs (CDCs), plasmacytoid (pDCs) and monocyte-derived 
DCs (moDCs). These cells can be identified by immunofluorescence as cells expressing the CD11c 
and MHCII marker. Moreover, the analysis of markers CD103 or CD11b and PDCA-1 or B220 
allows to discriminate between conventional and plasmacytoid subset, respectively (Kopf M, 2015, 
Nat Immunol). 
In the lungs, dendritic cells sampling antigens situated in basolateral side of the epithelium 
(Lambrecht BN, 2012, Annu Rev Immunol; Jahnsen FL, 2006, J Immunol). CD11b+ DCs lead 
mainly Th2 or Th17 response of helper T cells (Plantinga M, 2013, Immunity; Schlitzer A, 2013, 
Immunity), while CD103+ DCs have been associated with Th1 response (Furuhashi K, 2012, Am J 
Respir Cell Mol Biol). 
In case of viral infection, DCs migrate to lung-draining lymphonodes and trigger an antiviral 
response by lymphocytes T CD8+ (GeurtsvanKessel CH, 2008, J Exp Med) through CCR7, CD70 
expression and antigen cross presentation (Heer AK, 2008, J Immunol; Desch AN, 2011, J Exp 
Med; Ballesteros-Tato A, 2010, Nat Immunol). Conversely, under equilibrium conditions, the aim 
of DCs seems to be the maintenance of tolerance to non-pathogenic antigens (Oriss TB, 2005 J 
Immunol). 
4.1.2 Alveolar macrophages (AMs): 
Is another population closely involved in maintaining lung homeostasis, which colonize the alveoli 
in the first day of life (Guilliams M, 2013, J Exp Med). AMs differ from interstitial and bronchial 
macrophages for their function, location and live-turnover. 
In health condition, AMs is about 95% of the cell population contained in the alveoli together with 
a small number of T lymphocytes (Ely KH, 2006, J Immunol; Snelgrove RJ, 2011, Trends 
Immunol). They have reduced phagocytic capacity, compared to interstitial macrophages (Holt PG, 
1978, Am Rev Respir Dis) and low antigen presentation capacity (Lipscomb MF, 1986, J Immunol; 
Lyons CR, 1986, J Immunol; Toews GB, 1984, J Immunol). They also produce TGF-β that inhibits 
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lymphocytes activation and promotes regulatory T lymphocytes development (Roth MD, 1993, J 
Leukoc Biol; Coleman MM, 2013, Am J Respir Cell Mol Biol). Using F4/80, MHCII, CD11b and 
CD11c markers, AMs (CD11c
hi
 MHCII
lo
 CD11b
lo
) can be identified and differentiated from 
Interstitial macrophages (CD11c
lo
 MHCII
hi
 CD11b
hi
) (Becher B, 2014, Nat Immunol; Jakubzick C, 
2013, Immunity; Bedoret D, 2009, J Clin Invest; Guilliams M, 2013, J Exp Med; Schneider C, 
2014, Nat Immunol). 
Alveolar macrophages in health conditions have the duty to respond to infections by their 
activation, to eliminate apoptotic cells and to inhibit the activation of the immune system in the 
presence of harmless antigens. (Martinez FO, 2008, Front Biosci; Edwards JP, 2006, J Leukoc 
Biol; Mosser DM, 2008, Nat Rev Immunol). 
Alveolar macrophages are able to block immune response by inhibition of DCs mediated activation 
of T lymphocyte and through production of bioactive transforming growth factor-β, which in turn 
induce the generation of iTreg (induced regulatory T) cells from naïve CD4+ T lymphocyte 
(Strickland D, 1996, Immunology; Holt PG, 1993, J Exp Med; Thepen T, 1989, J Exp Med; 
Soroosh P, 2013, J Exp Med). 
Receptors expressed by alveolar macrophages allow a fine regulation of these cells by soluble 
mediators and trough cell-cell contacts. CD200R, SIRPα, Mannose receptor, MARCO, TREM2, 
IL10R, TGFβR are negative regulators of alveolar macrophages and are essential to prevent an 
unwanted inflammatory response against commensal bacteria and non-pathogenic antigens 
(Snelgrove RJ, 2008, Nat Immunol; Burger P, 2012, Blood; Oldenborg PA, 2000, Science; Steele 
C, 2003, J Exp Med; Neese LW, 1994, J Immunol; Gao X, 2013, Mol Med Rep; Habibzay, 2012, 
Mucosal Immunol; Morris DG, 2003, Nature). On the contrary, the binding of respective agonists 
to their receptors IL-1R, IFNGR, TNFR and TLRs expressed on AMs, transmit activator signals 
that inhibits the signal transduction of IL10R (Fernandez S, 2004, J Immunol), change the 
expression of the various TLRs on the cell (Maris NA, 2006, Eur Respir J; Oshikawa K, 2003, Exp 
Lung Res), induces the increase of phagocytic capacity (Lohmann-Matthes ML, 1994, Eur Respir J) 
and determines the production of pro-inflammatory cytokines (Steinmuller C, 2000, Am J Respir 
Cell Mol Biol). 
4.2 IMMUNE-SUPPRESSIVE CELLS IN TUMOR MICROENVIRONMENT 
The growth and tumor development may be promoted through a cross-talk between tumor cells and 
immune system cells, that exacerbates an immunosuppressive microenvironment. In this process 
are involved mainly myeloid-derived suppressor cells (MDSC), tumor associated macrophages 
(TAM) and dendritic cells, found in different types of cancer (Gabrilovich DI, 2012, Nat Rev 
Immunol; Qian BZ, 2010, Cell). These cells have been identified as responsible of the failure of 
numerous studies to evaluate different immunotherapeutic approaches in cancer and high density of 
these cells in tumors are often associated with poor prognosis and resistance to therapy (DeNardo 
DG, 2009, Cancer Cell; Steidl C, 2010, N Engl J Med; Mazzieri R, 2011, Cancer Cell). Moreover, 
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different studies demonstrated that TAMs and MDSCs depletion can re-establish the efficacy of 
immunotherapy (Srivastava MK, 2012, PloS One; Germano, 2013, Cancer Cell). 
TAMs and MDSCs accumulation in a tumor microenvironment is mainly caused by chemo-
attractants products derived from cancer cells. It has been reported that TAMs and MDSCs support 
tumor growth by different mechanisms: The block of anti-tumor response of lymphocyte T cells 
and natural killer (NK), the promotion of angiogenesis, the secretion of growth and proangiogenic 
factors and matrix-degrading enzymes (Gabrilovich DI, 2009, Nat Rev Immunol; De Palma M, 
2013, Cancer Cell). 
 
4.2.1 Myeloid-derived suppressor cells: 
are a heterogeneous population of myeloid progenitor cells that infiltrate all tumors (Ostrand-
Rosenberg S, 2012, Semin Cancer Biol). In mice MDSCs are characterized of CD11b
+
 Gr1
+
 
expression (Gabrilovich DI, 2012, Nat Rev Immunol). CD11b
+
Gr1
+
 myeloid progenitor cells are 
usually present in healthy mice, but they not have immunosuppressive activity and differentiate 
into mature myeloid cells. Conversely in tumor bearing mice, the differentiation is blocked and 
MDSC accumulates in different body district (Almand B, 2001, J Immunol; Diaz-Montero CM, 
2009, Cancer Immunol Immunother; Ostrand-Rosenberg S, 2009, J Immunol). 
These cells are divided into two subtypes: granulocytic and monocytic by the expression of surface 
markers. Granulocytic-MDSCs (G-MDSCs) (Ly6G
hi
Ly6C
low
) are much more than Monocytic-
MDSCs (M-MDSCs) (Ly6G
low
Ly6C
hi
), but their suppressive activity is lower compared to than 
activity of M-MDSCs (Youn J, 2008, J Immunol; Youn J, 2013, Nat Immunol; Movahedi K, 2008, 
Blood; Peranzoni E, 2010, Curr Opin Immunol). Distributed in the body, MDSCs are recruited into 
tumors site through chemokines, such as CCL2 or Bv8 (Huang B, 2007, Cancer Lett; Shojaei F, 
2007, Nature; Sawanobori Y, 2008, Blood; Sinha P, 2008, J Immunol) 
They promote tumor growth both through mechanisms involving suppression of other immune 
cells, and through non-immunologic mechanisms. For example, MDSC inhibit the activation of T 
lymphocytes through the production of ROS that down regulate the activity of the TCR (Ezernitchi 
AV, 2006, J Immunol; Nagaraj S, 2010, J Immunol) and the depletion from the microenvironment 
of arginine and L-cysteine required for their proliferation (Rodriguez PC, 2004, Cancer Res; 
Srivastava MK, 2010, Cancer Res). Moreover, they promote also the development of regulatory T-
cells through the production of IL-10, TGF-beta and CD40-CD40L (Huang B, 2006, Cancer Res; 
Pan PY, 2010, Cancer Res; Serafini P, 2008 Cancer Res). 
MDSC have been reported to also block the activity of the innate immune system, by inhibiting the 
cytotoxic activity and the IFN-gamma production of NK cells by cell-cell contacts. Membrane-
bound TGF-β1 on MDSCs induces anergy of NK cells (Li H, 2009, J Immunol; Liu C, 2007, 
Blood; Suzuki E, 2005, Clin Cancer Res; Elkabets M, 2010, Eur J Immunol). These cells also 
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inhibit NK cells activation through blocking the expression of NKG2D (Nausch N, 2008, Blood) 
(figure 5). 
 
Figure 5. 
Roles of MDSCs in tumor growth and progression. Summary of MDSCs immune-suppression mechanisms; these cells 
can suppress T cells activation and proliferation, lead induction of regulatory T cells and TAMs and suppress DC 
activity. .(from Shime H, 2015, Inflammation and Immunity in Cancer) 
 
4.2.2 Tumor-associated macrophages (TAMs): 
infiltrate various type of cancer both in humans and mice models (Solinas G, 2009, J Leukoc Biol) 
ad can induce tumor growth both through immunologic and non-immunological mechanisms. 
Studies with macrophages deficient models (Lin EY, 2001, J Exp Med) or macrophages depletion 
by bisphosfonate treatment (Sfondrini L, 2013, Int J Cancer) demonstrate that TAMs play an 
important role in growth and cancer progression. 
Tumor and stromal cells secrete many chemokine and chemoattractans that determine the 
recruitment of peripheral monocytes at tumor site. These cells evolve in TAM after 
microenvironment stimulation (Solinas G, 2009, J Leukoc Biol). 
Mantovani et al, reported two distinct activation states of macrophages, M1/M2 polarization states 
or classically/alternatively activation (Mantovani A, 2002, Trends Immunol; Biswas SK and 
Mantovani A, 2010, Nat Immunol). M1/M2-balance is regulated by immune signals (Hu X, 2007, J 
Leukoc Biol; Lawrence T, 2011, Nat Rev Immunol). JAK and STAT1 activation through interferon 
γ and β stimulation induce M1 phenotype in macrophage (Toshchakov V, 2002, Nat Immunol). In 
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other side JMJD3-IRF4 axis, STAT6, (PPAR)-γ stimulates M2 polarization (Satoh T, 2010, Nat 
Immunol; Charo IF, 2007, Cell Metab; Ishii M, 2009, Blood). 
Mantovani et al. (Mantovani A, 2008, Nature) demonstrate that gene expression of TAMs is mostly 
similar of in vitro M2-polarized macrophages. In the tumor microenvironment IL-4, TNF-α, TGF-
β, PGE2 and hypoxia affects M2 polarization of macrophages (Lewis CE, 2006, Cancer Res; 
Biswas SK and Mantovani A, 2010, Nat Immunol; DeNardo DG, 2009, Cancer Cell). 
TAMs are characterized by low expression levels of pro-inflammatory cytokine (IL12, IL6, 
IL1beta) and high levels of IL10, CD206, MMR and Arginase-1 that down regulate the activity of 
cytotoxic T lymphocytes, NK cells and DC. In addition, IL10 induces the activation of regulatory T 
cells. TAM also produce VEGF and PDGF that stimulate angiogenesis and matrix-degrading 
enzymes causing tissue remodeling in the tumor environment (Shime H, 2015, Inflammation and 
Immunity in Cancer; Mantovani A, 2008, Nature; Lin EY, 2007, Cancer Res) (figure 6). 
Figure 6. 
Roles of TAMs in tumor growth and progression. Circulating monocytes recruited by chemoattractant at tumor site and 
differ in TAMs with M2 phenotipe. TAMs induces immune-suppression and tumor development producing cytokines, 
proangiogenic and growth factors and matrix-degrading enzymes. .(from Shime H, 2015, Inflammation and Immunity in 
Cancer) 
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4.2.3 Dendritic cells: 
has the main function of antigen presentation to CD4+ and CD8+ lymphocytes, this process is 
inhibited due to a reduced maturation and increase of immature DCs in the tumor 
microenvironment (Ostrand-Rosenberg S, 2012, Semin Cancer Biol). Indeed, Tumor-associated 
dendritic cells (TADCs) weaken anti-tumor response and influence chemotherapy responses (Munn 
DH, 2004, Trends Mol Med; Gabrilovich D, 2004, Nat Rev Immunol; Jinushi M, 2013, Trends Mol 
Med). 
 
Therefore, the mutual interaction among these different immunological populations that 
accumulate in the tumor microenvironment causes an intensification of the immunosuppression, 
favoring tumor development. The depletion of these cells from the tumor microenvironment by the 
use of antibodies or the conversion through the TLRs ligands can induce a differentiation and 
maturation of tumor-associated myeloid cells, “re-educating” these cells and inducing a shift 
towards an antitumor phenotype. 
For example, a shift of TAMs versus a M1 phenotype through activation of immune signal of TLRs 
have been observed by several authors (Shime H, 2012, PNAS; Akazawa, 2007, PNAS; Azuma M, 
2012, Oncoimmunology; Seya T, 2012, Oncoimmunology). Moreover, Eriksson et al., reported that 
the use of Bacteriophages determines production of M1-like cytokines and expression of proteins 
related to antigen presentation in TAMs (Eriksson F, 2009, J Immunol). Shime at al. demonstrated 
that Poly(I:C) administration on tumor-bearing mice result in a M1 polarization of TAMs with a 
delay of tumor growth (Shime H, 2012, PNAS) (figure 7). 
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Figure 7. 
M1 phenotype shift of TAMs by TLR pathway. TLR agonists, such as CpG-ODN and Poly(I:C), are able to induce re-
education of M2 TAMs to a M1 Macrophages. M1 tumor associated macrophages produce type I IFNs, IL-12 and other 
Th1 cytokines that induce the activation of CTLs and NK cells. Moreover, M1 TAMs produce TNF-alpha that is 
responsible of killing of tumor cells.(from Shime H, 2015, Inflammation and Immunity in Cancer) 
 
TRL ligands can also modify immunosuppressive activity of MDSCs. Tumor injection of CpG-
ODN stimulates MDSCs to differentiate into M1 macrophage and to lose their suppressive activity 
on T cells (Shirota Y, 2012, J Immunol). Moreover, Toll Like Receptors signal have been 
demonstrated to induce Type-I IFNs production that in turn can modulate the function of MDSCs 
and CpG-ODN and Poly(I:C) have been reported to induce Type-I IFNs secretion by pDCs, which 
result in MDSCs maturation (Zoglmeier C, 2011, Clin Cancer Res; McCartney S, 2009, J Exp 
Med) (figure 8). 
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Figure 8. 
Conversion of MDSCs activity by TLRs pathway. TLR3 and 9 agonists and type I IFNs induces maturation and activation 
of MDSCs, which result in a direct cytotoxic activity on tumor and IFN-alpha production that active NK cells cytotoxic 
activity. .(from Shime H, 2015, Inflammation and Immunity in Cancer) 
 
4.3 PRECLINICAL STUDIES WITH TRL AGONISTS FOR THE 
TREATMENT OF LUNG CANCER 
4.3.1 Preclinical studies with TRL9 agonists 
Preclinical studies in murine models have shown limited efficacy of CpG-ODN in promoting 
antitumor activity in the lung. In fact, the CpG-ODN result capable to control the growth of lung 
metastases only when administered before injection of tumor cells or in a state of minimal disease. 
A study evaluated the efficacy of CpG-ODN in controlling the development of metastasis induced 
by i.v. injection of N202.1A cells, derived from a spontaneous mammary carcinoma. The results 
showed that the growth of the metastasis was inhibited only when the systemic treatment with 
CpG-ODN, was carried out immediately before or immediately after the inoculation of tumor cells, 
but not when the CpG-ODN was administered 2 days after tumor injection. Therefore, the study 
has indicated that repeated systemic CpG-ODN injection in this tumor model is able to prevent the 
tumor grow in the lung, but is poorly effective when administered few days after tumor injection 
(Sfondrini L, 2002, FASEB J). 
Kim et al. (Kim HA, 2009, Cancer Lett) evaluated the ability of CpG-ODN in preventing the 
growth of lung metastases derived from intravenous inoculation of B16F10 murine melanoma 
cells. In this study, CpG-ODN was administered i.p. at day -7 or -3 before B16F10 injection, or at 
day of injection. Fourteen days after inoculation animals were sacrificed and the number of lung 
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colonies was counted. In this study, a reduction of 62%, 82% and 54% in the number of lung 
metastases was observed in the groups treated at day -7, -3 and 0 before the injection, compared to 
the group control. 
To evaluate the therapeutic effect of CpG-ODN on the growth of already implanted B16F10 
melanoma cells, the experiment was repeated administering the oligonucleotide after tumor 
injection. Although CpG-ODN treatment induced a significant inhibition in lung tumor 
colonization, the inhibition was much lower compared to the CpG-ODN administration before 
tumor injection. 
The therapeutic activity of CpG-ODN in countering tumor growth in the lungs was evaluated in 
another study (Sorrentino R, 2010, J Immunol). The aim of this study was to clarify the effect of 
CpG-ODN in the murine Lewis lung carcinoma model and to evaluate the immune populations 
activated by CpG-ODN. The mice were inoculated i.v. with LLC1 cells and 10 days after injection, 
CpG-ODN was administered i.p. The animals were sacrificed 3 or 7 days after administration. The 
results of this study have shown that a single administration of CpG-ODN induced an increased 
tumor growth evaluated 3 and 7 days after treatment. 
The study shows that CpG-ODN increased an immunosuppressive environment in the lung 
associated with an increased influx of plasmacytoid dendritic cells (pDCs), that resulted in turn 
responsible of an increased recruitment of T regulatory cells. Depletion of pDCs by a specific Ab 
(m927) in mice treated with CpG was able to revert this immuno-suppressive environment, 
resulting in an increased percentage of activated myeloid dendritic cells, CD8+ T lymphocytes and 
an increased production of Th1 and Th17-like cytokines. The induction of this type of immune 
response in the animals treated with CpG-ODN in combination to pDC depletion was associated 
with a reduction of the tumor size. 
Therefore, this study shows that treatment with CpG-ODN in this model of lung cancer induced an 
increase in tumor growth linked to the increased of the immunosuppressive environment. 
Yan et al. (Yan J, 2012, Acta Pharmacol Sin) evaluated an immunotherapeutic approach against 
tumor metastases, based on combination of activatory anti-TLR2 antibodies with CpG-ODN. 
C57BL/6 mice were inoculated i.v. with melanoma B16-F10 cells and mice were treated with CpG-
ODN (0.5 mg/kg) or with the anti-TLR2 antibody (200 mg/kg) alone, or in combination. 
The results of this study revealed that only treatment with the CpG-ODN in combination anti-TLR2 
antibody resulted able to suppress significantly the growth of metastases compared to single 
treatments. Indeed, combinatory treatment induced a higher infiltration of NK cells, CD8+ T 
lymphocytes, a reduced recruitment of M2 macrophages and of regulatory T cells and a reduced 
expression of immunosuppressive factors (TGF-β1, cyclooxygenase-2 and indoleamine 2,3-
dioxygenase). The anti-metastatic effect of the combination therapy was confirmed also in a 
metastatic spontaneous mouse model of Lewis lung carcinoma. Therefore, the study demonstrated 
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that combination of TLR9 agonist with an anti-TLR2 antibody is able to eliminate 
immunosuppressive factors from the tumor, that block an effective immune response. 
 
4.3.2 Preclinical studies with TRL3 agonists 
Several studies have shown remarkable efficiency in the use of TLR3 agonists in the treatment of 
lung cancer or lung metastases. Poly(I:C) has proved to be able to induce a conversion of the 
tumor associated macrophages (Shime H, 2012, PNAS; Shime H, 2014, J Innate Immun) 
(immunosuppressive phenotype) on anti-tumor macrophages, able to have a direct effect on the 
tumor (Forte G, 2012, J Immunol; Ly LV, 2010, J Immunol; Hervieu A, 2013, J Invest Dermatol; 
Sfondrini L, 2004, Cancer Immunol Immunother; Glasner A, 2012, J Immunol) and to induce 
activation of the immune system (Talmadge JE, 1985, Cancer Res; Ebihara T, 2010, J Exp Med). 
Shime H et al. (Shime H, 2012, PNAS) showed as Poly(I:C) injection in a model of LLC 
carcinoma was able to trigger a shift of TAM to macrophage with a M1 phenotype. LLC bearing 
mice treated with Poly(I:C) shown increased TNF-α production by TAMs and expression of M1-
related genes, which in turn induced hemorrhagic tumor necrosis and block of tumor growth. This 
effect was not observed in TNF-α-/- and Ticam-1-/- mice. This study demonstrated that the 
conversion of a microenvironment that supports the tumor to an anti-tumor microenvironment 
through the administration of the TLR3 agonist is able to efficiently block tumor growth. 
The same group of researchers demonstrated that Poly(I:C) treatment induces maturation and 
activation of MDSCs, making them competent for priming of NK cells, that activated produce 
IFNγ. The maturation of the MDSC and NK cells activation results in a reduction in tumor 
growth. This effect is partially abrogated in Ticam-1-/- and MAVS-/- mice and totally in the 
double KO mice (Shime H, 2014, J Innate Immun). 
Another study evaluated the effect of TLR3 agonists administration on B16 induced metastatic 
lung cancer. Mice were i.v. injected with B16 melanoma cells and after one week treated with 
Poly(I:C) i.p. After 9, 5 or 10 days from melanoma cells injection, mice were sacrificed and 
metastases were counted. 
Poly(I:C) treatment resulted in a growth reduction of lung metastases due to activation of dendritic 
cells and IFNγ and IL17A production, which in turn induced the recruitment into the lung of 
several cells types with cytotoxic activity as NKT and CD8+ lymphocytes. This study shows that 
the activation of the immune system and the simultaneous reduction of an immunosuppressive 
microenvironment are able to effectively counteract the growth of lung metastases (Forte G, 2012, 
J Immunol). 
 
4.4 LOCAL DELIVERY OF TLR AGONIST 
Several studies (De Cesare M, 2010, J Immunother; De Cesare M, 2008, Clin Cancer Res; 
Sommariva M, 2011, Cancer Res; Lou Y, 2011, J Immunother) suggested that the route of 
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administration is a critical factor in influencing the activity the CpG-ODN. A greater anti-tumor 
effect was observed when the CpG-ODN was inoculated directly and repeatedly in tumor growth 
site, where ensures effective and continuous activation and recruitment of both innate and adaptive 
immune response.  
Indeed, the anti-tumor activity of CpG-ODN showed limited efficacy in the therapy of lung cancer. 
Various studies in preclinical models show that the CpG-ODN is capable of controlling the growth 
of lung metastases only when administered before tumor injection, or immediately after in a state 
of minimal disease (Sfondrini L, 2002, FASEB J; Kim HA, 2009, Cancer Lett; Sorrentino R, 2010, 
J Immunol). Moreover, was not observed any benefit from the addition of CpG-ODN 
administration to chemotherapy in phase III clinical trials in patients with non-small cell Lung 
Cancer (NSCLC) (Jahrsdorfer B, 2008, Update Cancer Ther; Kelly RJ, 2010, Clin Lung Cancer). 
Thus, a local, instead of systemic, TLR9 agonists administration, could be a novel approach to 
improve the therapeutic efficacy of CpG-ODN in the treatment of lung cancer or preventing lung 
metastases derived from different primary tumors.  
 
4.4.1 Experimental approaches for local delivery of therapeutic agents in the 
lung 
Bronchial and bronchoalveolar airways are accessible via the endobronchial space. Intranasal 
administration to deliver the CpG-ODN in the lungs was evaluated in different experimental 
models showing its adjuvant activity and its therapeutic potential in the treatment of asthma and 
respiratory infections by pathogenic agents (Pal S, 2002, Infect Immun; Choudhury BK, 2002, J 
Immunol; Kline JN, 2007, Immunol Res; Juffermans NP, 2002, Infect Immun; Edwards L, 2005, 
Eur J Immunol; Deng JC, 2004, J Immunol; Pesce I, 2010, J Innate Immun). Moreover, Pesce 
(Pesce I et al, 2010, J Innate Immun) have well-characterized local immunomodulatory effects of 
CpG-ODN in the lung when administered by this route. 
Intranasal administration, however, is not applicable in a clinical setting, where inhalers (device 
used for inhalations) or nebulizers (device which reduces a liquid into fine droplets and spreads in 
the air), which are the most convenient and simple approach to repeated application and to ensure a 
uniform distribution and penetration in the pulmonary alveoli, are generally used. 
Several studies in mice have evaluated the use of aerosol administration of various therapeutic 
agents in the lung. In particular, this approach has been used to administer: cytokines as  
interleukin-12 (Jia SF, 2003, Clin Cancer Res), interleukin-2 (Khanna C, 1997, Cancer) and 
stimulating granulocyte/macrophage factor (Anderson PM, 1999, Clin Cancer Res); 
chemotherapeutic agents such as gemcitabine (Koshkina NV, 2005, Int J Cancer) and docetaxel in 
combination with celecoxib (Haynes A, 2005, Pharm Res); antisense oligonucleotides alone or in 
combination with anticancer drugs (Templin MS, 2000, Antisense Nucleic Acid Drug Dev; 
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Garbuzenko OB, 2010, PNAS) and proteins as Protein Kinase Kinase 4 mitogen-activated (Lee HY, 
2002, Clin Cancer Res), PTEN (Kim HW, 2004, Cancer Res). 
The conclusion derived from these studies is that the local administration of these molecules by 
aerosols allows their location at the level of the bronchial epithelium, alveolar epithelium, 
endothelium. Moreover, compared to systemic administration, this route of administration results in 
a better retention of the different agents in the lungs, minimizes their penetration into the systemic 
circulation, and thus limits adverse side effects. 
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AIM 
TLRs recognize several conserved pathogen-associated molecular patterns, allowing to detect 
microbial pathogens. Toll-like receptors agonists, in light of their immunostimulatory activity, are 
included in the National Cancer Institute list of immunotherapeutic agents with the highest 
potential to cure cancer. Our and other previous studies in experimental and clinical cancers 
highlighted the importance and the superior antitumor activity of the locoregional delivery of TLR 
agonists compared to the systemic administration, revealing the relevant role in this activity of 
innate immune cells, that must be activated locally unlike cells of the adaptive immune response, 
which can reach the antigen wherever they are activated. 
Since bronchial and bronchoalveolar tumors are accessible via the endobronchial space, lung 
cancers are candidate tumors for taking advantage of local delivery. Several therapeutic agents, 
such as cytokines, oligonucleotides and chemotherapeutic agents have been explored for 
inhalation delivery in malignancies. These studies demonstrated the feasibility of aerosol delivery, 
its potential anti-tumor effects and the reduced side-effects compared to systemic treatment. Thus, 
inhalation of aerosolized TLR agonists could represent a convenient and simple approach to 
treat/prevent primary lung cancer and lung metastases and might favour frequent local 
replenishment of innate immune effectors. 
Our previous studies showed that aerosolized CpG-ODN, TLR9 agonist, was able to reach the 
bronchoalveolar space, locally activated an immune response without any signs of toxicity and 
was more efficacious than systemic administration against lung metastases of N202.1A mammary 
carcinoma cells. In contrast, aerosol delivery of CpG-ODN was not very effective against 
metastases of B16 melanoma cells, which selectively recruit CD68+ M2 macrophages and induce 
an immunosuppressive environment that hinder the recruitment of NK cells. Studies in mice 
showed that Poly(I:C), TLR3 agonist, through the TICAM-1/TRIF adaptor was able to convert 
lung tumor-associated macrophages (TAM) from tumor supporters (M2) to those with tumoricidal 
properties (M1). Thus, aerosol-delivered TLR3 agonists could increase the antitumor activity of 
CpG-ODN even in the presence of an immunosuppressive tumor microenvironment. 
Besides TAM, other immune populations can contribute to the tumor-induced immunosuppressive 
microenvironment. MDSCs represent one of the most relevant of these populations that 
progressively accumulate within the tumor mass and suppress effector cell function both directly 
and by amplify the macrophage immunosuppressive activity through a continuous cross-talk. 
Therefore, the microenvironment is a critical factor for successful use of immunotherapies with 
immunomodulants, and strategies to shift a tumor-supporting milieu to a host-friendly one might 
lead to improved antitumor activity of TLR agonists. Thus, the aim of this project of thesis are to: 
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1) Evaluate the combined aerosol administration of Poly(I:C)/CpG-ODN to simultaneously 
blocking TAM-induced immunosuppression and maintain a continuous activation of innate 
immune cells in the treatment of experimental B16 melanoma lung metastases. 
2) Investigate the mechanism by which the two combined agonists could induce the activation of 
effector cells population. 
3) Develop strategies to locally shape a lung microenvironment that further could favor effector 
cells activation against B16 melanoma lung metastases, by combined inhalation-based 
immunotherapies. 
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MATERIAL AND METHODS 
1. Cell lines, culture and reagents 
B16 mouse melanoma cells and YAC-1 mouse lymphoma cells (ATCC) were routinely 
maintained at 37°C in a 5% CO2 atmosphere in Dulbecco’s modified Eagle’s medium (DMEM, 
Gibco) and RPMI-1640 (EuroClone), respectively, supplemented with 10% fetal bovine serum 
(FBS, Gibco) and 2 mM glutamine (LONZA). Purified phosphorothioated TLR-9 agonist 
ODN1826 (5’-TCCATGACGTTCCTGACGTT-3’), containing CpG motifs (CpG-ODN), was 
synthesized by TriLink Biotechnologies. Low-molecular-weight polyinosinic-polycytidylic acid 
(poly(I:C)), a synthetic analog of the double-stranded RNA (dsRNA) agonist of TLR-3, was from 
InvivoGen. 
51
Cr (1 mCi) was purchased from Perkin-Elmer (Waltham). Dacarbazine was provided 
by Medac GmbH. Intron A (interferon-alpha-2b recombinant) was provided by Schering-Plough. 
InVivo MAb anti-mouse Ly6G (Gr-1), RB6-8C5, was from Bio X Cell. 
Bronchoalveolar lavage (BAL) was performed in euthanized mice by 5 intratracheal instillations 
of 1 ml PBS, containing 0.5% BSA and 2 mM EDTA, followed by gentle aspiration. The 
recovered BAL fluid was then centrifuged. The resulting cells were plated for 2 hr at 37°C to 
allow macrophages to adhere to the culture plates, and non-adherent cells were removed by 
washing with PBS. To evaluate NK cell degranulation and the composition of lung immune cells, 
lungs from mice that were injected with tumor cells and treated with CpG-ODN, poly(I:C), IFN-α, 
RB6-8C5 and Dacarbazine were digested in DMEM that contained collagenase (300 U/ml) and 
hyaluronidase (100 U/ml) (Stemcell Technologies) for 1 hr at 37°C. Cell suspensions were filtered 
through 70-µm cell strainers (Falcon), and after red blood cell lysis by incubation in 1x RBC 
Lysis Buffer Solution (eBiosciences), they were analyzed by flow cytometry or plated for 2 hr 
37°C to separate adherent cells, containing primarily macrophages, from non-adherent cells, 
containing effector cells, such as NK cells. Splenocyte preparations were obtained by gently 
flushing the spleen in serum-free RPMI 1640 to release the cells. After red blood cell lysis by 
incubation in 1x RBC Lysis Buffer Solution (eBiosciences), naive NK cells were purified using 
the Mouse NK Cell Isolation Kit II and MACS separation columns (Miltenyi), according to the 
manufacturer’s instructions. 
 
2. Mice and experimental protocols 
All experiments were carried out using 6- to 12-week-old female C57BL/6 mice (Charles River) 
maintained in laminar-flow rooms at constant temperature and humidity, with food and water 
given ad libitum. Experiments were approved by the Ethics Committee for Animal 
Experimentation of the Fondazione IRCCS Istituto Nazionale dei Tumori of Milan according to 
the Declaration of Helsinki regarding the use and care of animals. Mice were injected 
intravenously with 5×10
5
 B16 melanoma cells and treated starting 4 or 7 days later with aerosol at 
 35 
 
72- to 96-hr intervals or with dacarbazine administered intraperitoneally at 70 mg/Kg, 5 
days/week for 3 or 2 weeks, respectively. Mice were weighed twice weekly. 
CpG-ODN1826, Poly(I:C) and Intron A were aerosolized using a whole-body exposure system 
(EMMS) as described (Sfondrini L, 2013, Int J Cancer). Briefly, Poly(I:C) (15 mg), CpG-ODN 
(1.5 mg) or Intron A (4,000.000 IU) were dissolved in 5 ml of saline and placed in the nebulizer to 
treat up to 10 mice placed in the aerosol box and exposed to aerosol for 15 min. The monoclonal 
antibody RB6-8C5 was administered endotracheally (Guilleminault L, 2014, J Control Release; 
Herve V, 2014, MAbs). Briefly, mice were anesthetized and given 25 μg/mouse of RB6-8C5 MAb 
using a Microsprayer Aerosolizer Model IA-1C connected to a FMJ-250 high-pressure syringe 
(Penn-Century) introduced just before the first trachea bifurcation (Bivas-Benita M, 2005, Eur J 
Pharm Biopharm). In all experiments, mice were weighed twice weekly, euthanized at the end of 
experiments and macroscopic lung metastases counted. All in vivo experiments were repeated at 
least twice. 
 
3. Histological, immunofluorescence and immunohistochemical 
examination of lungs 
Lung samples obtained from healthy mice or from mice i.v. injected with B16 cells and treated 
with aerosolized Intron A, CpG-ODN, Poly(I:C), or CpG-ODN/Poly(I:C) as described above or 
untreated were fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned at 5 mm 
and stained with hematoxylin and eosin for histological evaluation by light microscopy (Scan 
Scope Aperio, Nikon). 
Immunofluorescence and immunohistochemical analyses were performed to analyze macrophage 
infiltration on lung sections collected from mice after i.v. injection of B16 cells (4 mice/group) 
untreated or treated with aerosolized CpG-ODN alone or combined with Poly(I:C). For 
immunohistochemistry, tissue samples were fixed in 10% buffered formalin and paraffin-
embedded, sectioned (4-µm thick), deparaffinized and rehydrated. Antigen unmasking was 
performed using pH 9 Tris/EDTA buffer (Novocastra) in a PT Link Dako unit at 98°C for 30 min. 
Sections were then brought to room temperature and washed in PBS. After neutralization of 
endogenous peroxidase with 3% H2O2 and Fc blocking by a specific protein (Novocastra), 
samples were incubated with polyclonal rabbit anti-mouse arginase antibody (1:200, Genetex 
International Corp.) or polyclonal rabbit anti-mouse CD163 antibody (1:100, Abcam) for 1 hr at 
room temperature. Staining was revealed by a polymer detection kit (Novocastra) and AEC (3-
amino-9-ethylcarbazole, Dako) substrate-chromogen. Slides were counterstained with Harris 
hematoxylin (Diapath). For immunofluorescence analysis, polyclonal rabbit anti-mouse CD68 
(1:100, Abcam) and rat anti-mouse IL-10 (1:200, Novus Biologicals) were used. Antigen 
unmasking was performed using pH 6 citrate buffer (Novocastra) in a PT Link Dako unit at 98°C 
for 30 min. After Fc blocking, primary antibody binding was revealed by Alexa 488-conjugated 
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goat anti-rat (Invitrogen Molecular Probes) and Alexa 568-conjugated goat anti-rabbit (Invitrogen 
Molecular Probes) secondary antibodies. Rat isotype control (eBioscience Rat IgG1 isotype 
control) and an unrelated rabbit antibody (Invitrogen Rabbit isotype control), used as controls to 
verify the specific reactivity of arginase and IL-10 staining, did not reveal any staining. Slides 
were counterstained with DAPI nucleic acid stain (Invitrogen Molecular Probes). All sections 
were analyzed under a Leica DM2000 optical microscope (Leica Microsystems) and 
microphotographs were collected using a Leica DFC320 digital camera (Leica). 
 
4. Quantitative PCR Analysis 
Lung samples of mice bearing B16 melanoma cells treated with dacarbazine or untreated were cut 
into small pieces and homogenized with QIAzol Lysis Reagent (QIAGEN). Total RNA was 
isolated according to the manufacturer’s instruction and reverse transcription was performed using 
SuperScript III First-Strand (Invitrogen). Real-time PCR was performed with Power SYBR Green 
PCR Master Mix (Applied Biosystems) with a StepOne Real-Time PCR System (Applied 
Biosystems), using the following primers: RAE1 rev: 5’-CCC TCC TCT GGC CTC TCC TT -3’; 
RAE1 for: 5’-CCC CAG TAT CAC CCA GCT TAC AT-3’; MULT1 rev: 5’-CAT CCA AGA 
GAG GTG GTG GT-3’; MULT1 for: 5’-AGC TCA TGT TGC ACT GGA AA-3’. Expression of 
the gene was normalized to GAPDH.  
Lungs from healthy or tumor-bearing mice untreated or treated were digested in DMEM medium 
containing collagenase and hyaluronidase as described above, while naïve macrophages were 
isolated from healthy mice and co-cultured for 24 hours at a 1:1 ratio with non-adherent cells from 
tumor-bearing lungs of mice that were treated with or without aerosolized CpG-ODN/poly(I:C). 
At the end of the co-incubation, macrophages and lung cell suspensions were incubated with 
QIAzol Reagent (QIAGEN) and total RNA was isolated according to the manufacturer’s 
instructions. Reverse transcription was performed using the High-Capacity RNA-to-cDNA Kit 
(Applied Biosystems), and real-time PCR was performed using TaqMan® Fast Universal PCR 
Master Mix (Applied Biosystems) and SDS 2.4 on a 7900HT Fast Real-Time PCR System 
(Applied Biosystems), with the following TaqMan® gene expression assays (Applied 
Biosystems): Arg1 (Mm00475988_m1), Nos2 (Mm00440502_m1), IL-10 (Mm01288386_m1), 
IL-12 (Mm00434169_m1), IRF-4 (Mm00516431_m1), IRF-5 (Mm00496477_m1), ALOX15 
(Mm00507789_m1), IL-6 (Mm00446190_m1), STAT-1 (Mm00439531_m1), STAT-6 
(Mm01160477_m1), IFNγ (Mm01168134_m1), IL15 (Mm00434210_m1), and IL15Ra 
(Mm04336046_m1). Expression of each gene was normalized to ActB (Mm00607939_s1) and 
B2M (Mm00437762_m1). 
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5. Multi-parameter flow cytometry 
Cell suspensions were stained for 30 min at 4°C with the following directly conjugated antibodies: 
CD45APCeFluor780 (eBioscience, 30-F11); CD3ePE (Miltenyi, 145-2C11); CD49bFITC 
(Miltenyi, DX5); CD69APC (Miltenyi, H1.2F3); CD314PeVio770 (NKG2D, Miltenyi, CX5); 
CD11bPE (BD, M1/70); CD11cPE-Cy7 (eBioscience, N418); F4/80PerCPCy5.5 (eBioscience, 
BM8); IL15Ra APC (R&D System, #888220); Ly6G PERCPVio700 (Miltenyi, 1A8); Ly6C APC 
(eBioscience, HK1.4); CD4PEVio770 (Miltenyi, REA604); CD8PeCy5 (eBioscience, 53-6.7). 
Purified rat anti-mouse CD16/CD32 monoclonal (eBiosciences, 93) was used to prevent 
nonspecific binding to mouse Fc receptors. Cells were examined using a FACSCanto flow 
cytometer (BD) and data were analyzed using FlowJo software (TreeStar). All analyses were 
performed gating on CD45+ cells that fell within the lymphocyte population (FSClowSSClow) 
after doublet exclusion to detect NK cell infiltrate. To detect expression of NKG2D ligands, B16 
melanoma cells cultured for 24 hr in complete medium supplemented or not with different 
concentrations of dacarbazine (0.2, 0.4, 0.6, 0.8, 1.0, 1.2 g/l) were washed, stained for 30 min at 
4°C with RAE1γPE (eBioscience, CX1) or MULT1PE (eBioscience, 5D10) or Isotype control 
(eBioscience, 14-4031 and 14-4888) and analyzed by FACScanto as above. 
 
6. In vitro NK degranulation and cytotoxic assays 
To evaluate NK cell degranulation, CD107a mobilization was assayed. Briefly, lungs from mice 
injected with tumor cells and treated for 2 weeks with aerosolized CpG-ODN/Poly(I:C) or with 
dacarbazine alone or combined with aerosol CpG-ODN/Poly(I:C) (4 mice/group) or left untreated 
were digested in DMEM medium containing collagenase/hyaluronidase and lung suspensions 
were re-stimulated in vitro by co-culture with B16 melanoma cells. After 24 hr, non-adherent cells 
were collected and incubated in FACS tubes with B16 tumor cells (60:1) and CD107a-APC 
LAMP1 antibody (Miltenyi, 1D4B) for 1 hr at 37°C. Monensin (eBiosciences) was added to a 
final concentration of 6 µg/ml and cells were incubated for an additional 3 h at 37°C. Fifteen 
minutes before the end of the incubation, cells were stained with CD3FITC (Miltenyi, 17A2), 
CD49PE (Miltenyi, DX5) and CD45APCeFluor780 (eBiosciences, 30-F11) antibodies. After 
washing, cells were resuspended in FACS Buffer, 7AAD (BD) was added to each tube and cells 
were analyzed by flow cytometry as described above. For in vitro cytotoxicity assay, lung 
suspensions were plated in 24 wells plate for 2 h at 37°C; non-adherent cells were then recovered 
and co-cultured in 96 wells U-bottom plate for 12 hr with 2×10
4
 B16 tumor cells (5:1) labelled 
with CFSE (Life Technologies) according to manufactured protocol. After incubation, cells were 
harvested, 7AAD was added to each sample and cytotoxicity evaluated by flow cytometry 
assessing the percentage of CFSE+ 7AAD+ cells. 
NK cell-mediated cytotoxicity and the ability of adherent cells from lung immune infiltrates of 
mice to modulate activity of splenic naïve NK cells was evaluated by measuring cytotoxic activity 
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on 
51
Cr-YAC-1 target cells. In the first experiment, spleen-derived NK cells were treated in vitro 
with or without poly(I:C) (100 µg/ml) and CpG-ODN (1 µM) for 24 hours. In a second 
experimental setting, BAL-derived macrophages were treated in vitro with or without CpG-
ODN/poly(I:C), as before. Twenty-four hours later, treated macrophages were washed extensively 
or not to eliminate TLR agonists from the cell culture. NK cells were then added to macrophages 
and cocultured for another 24 hours. At the end of each experiment, NK cells were harvested and 
used for the cytotoxicity assay. Specifically, YAC-1 target cells were labeled with 100 μCi 51Cr 
(PerkinElmer) for 1 hr at 37°C, washed 3 times with PBS-5% FCS, and resuspended in 
RPMI1640, containing 10% FBS. NK cells were then coincubated with YAC-1 target cells at an 
effector:target ratio of 50:1 in triplicate 96-well U-bottomed plates for 4 hours at 37°C.  
Lungs from tumor cell-injected mice untreated or treated were digested in DMEM medium 
containing collagenase/hyaluronidase and suspensions were plated for 2 hr at 37°C to separate 
adherent cells containing mostly macrophages from non-adherent cells containing effector cells. 
Adherent cells were washed and cultured at a 1:1 cell ratio with naive NK cells purified from 
spleen of C57BL/6 mice by NK Cell Isolation Kit II mouse (Miltenyi). After 24 hr, non-adherent 
cells were collected and incubated for 4 hr at 37°C at an effector:target ratio 50:1 in triplicate 96-
well U-bottomed plates with YAC-1 target cells labeled with 100 μCi 51Cr (PerkinElmer) for 1 hr 
at 37°C and washed 3 times with PBS-5% FCS.  
To assess cytotoxic activity of effector cells of untreated or treated mice, lungs were 
enzymatically digested as above and lung suspensions were plated for 2 hr at 37°C to collect non-
adherent cells containing effector cells. B16 melanoma and YAC-1 target cells were labeled with 
51
Cr as above and incubated for 4 hr at 37°C with non-adherent cells at an effector:target ratio of 
50:1. Radioactivity of the supernatant (80 μl) was measured with a Trilux Beta Scintillation 
Counter (PerkinElmer). Percent specific lysis was calculated as: 100 × (experimental cpm - 
spontaneous cpm) / (maximum cpm - spontaneous cpm). 
 
7. ELISA Assay 
Concentrations of cytokines in the culture supernatants were measured using ELISA kits for IL-6 
(eBioscience), IL-10 (eBioscience), and IL-12 (R&D System). 
 
8. Statistical analysis  
PCR data were analyzed using the 2^
-ΔCt
 method. In all experiments, differences between groups 
were compared using two-tailed unpaired student’s t-test and were considered to be significant at 
p < 0.05. 
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RESULTS 
1. Association of TLR3 agonist with aerosolized CpG-ODN reduce the 
number of Arg+ IL-10+ tumor associated macrophages and increases 
recruitment of NK cells 
In order to evaluate whether TLR3 agonist, Poly(I:C), was able to reach the alveoli and recruit 
immune cells, C57BL/6 mice were treated with Poly(I:C) administered by aerosol (15 mg 
dissolved in 5 ml of PBS to treat up to 10 mice in the same aerosol box). Cytofluorimetric analysis 
of lung infiltrate obtained after enzymatic digestion from mice treated with Poly(I:C) aerosol 
showed a significant increase of macrophages and dendritic cells, as compared to saline-treated 
mice (figure 9). 
 
 
Figure 9. 
Percentage and representative 
dot plots of macrophages 
(CD11c-F4/80+ cells among 
CD45+ cells) (A), and 
dendritic cells (CD11c+F4/80- 
cells gated on CD11b+ cells) 
(B), obtained by enzymatic 
digestion of lungs from mice (4 
mice/group) treated 3 times at 
24-h intervals with aerosolized 
TLR3 agonist poly(I:C) (15 
mg) or saline. *p<0.05. 
 
Studies previously performed in our laboratory to evaluate aerosol delivery of CpG-ODN, agonist 
of TLR9, as a strategy for local administration of immunostimulators, have showed that 
aerosolized CpG-ODN reached the bronchoalveolar space, locally activated an immune response, 
and was more efficacious than systemic administration against lung metastases of N202.1A 
mammary carcinoma cells. In contrast, aerosol delivery of CpG-ODN was minimally effective 
against metastases of B16 melanoma cells (Sfondrini L, 2013, Int J Cancer), which selectively 
recruit CD68+ macrophages with an M2 phenotype and induce an immunosuppressive 
environment in the lung (Gil-Bernabe A, Blood, 2012). 
Therefore, we evaluated whether combination of Poly(I:C), reported able to convert tumor-
associated macrophages from tumor supporters (M2) to those with tumoricidal properties (M1) 
(Shime H, 2012, PNAS; Shime H, 2014, J Innate Immun), was able to improve the CpG-ODN-
induced antitumor response in B16 lung metastases model. 
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To assess if aerosolized Poly(I:C)/CpG-ODN combination could induce modification of lung 
immune infiltrates and affect tumor-induced recruitment of TAMs, C57BL/6 mice were i.v. 
injected with 5×10
5
 B16 melanoma cells and treated twice weekly starting 4 days after tumor cell 
injection with aerosolized Poly(I:C) combined to CpG-ODN or with aerosolized CpG-ODN alone. 
Immunohistochemical analysis on lung sections obtained 3 weeks after tumor injection from mice 
treated with two aerosolized agonists highlight a significant reduction of arginase-positive 
macrophages number, as compared to untreated mice (16,4 ± 2,1 versus 24.7 ± 2.2; p=0.015), 
while not significant reduction of arginase-positive macrophages was detectable in the lungs of 
mice treated with CpG-ODN alone (20,6 ±2,6) (figure 10a). 
Double immunofluorescence analysis revealed a reduction of CD68+ IL10+ macrophage mostly 
in mice treated with the combination of the two TLR agonists confirming the reduction of M2 
macrophages (figure 10b). 
Figure 10. 
Immunohistochemical staining for arginase I positive and CD163 positive (A) macrophages in formalin-fixed, paraffin-
embedded lung tissue collected after i.v. injection of 5×105 B16 melanoma cells from mice treated with aerosolized 
CpG-ODN alone or combined with Poly(I:C) or left untreated (3-4 mice/group). Original magnification X400; Inset in 
upper right panel is a higher-magnification (X630) showing the cell morphology of macrophages infiltrating the lungs 
of untreated mice. Histograms in the bottom show the mean number of arginase I-expressing or CD163-expressing 
macrophages in lung tissue evaluated on 10 fields/group. *p<0.05; ***p <0.001.  Representative immunofluorescence 
images of lung samples showing M2-polarized macrophages as CD68 (red)-positive cells also expressing IL-10 (green) 
(B). Original magnification X400.  
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We therefore assessed whether this combination could result in an increased recruitment of 
effectors cells in the lung tumor microenvironment, particularly focusing on NK cells, since their 
pivotal role in protection against B16 tumor (Sfondrini L, 2004, Cancer Immunol Immunother; 
Glasner A, 2012, J Immunol; Zheng S, 2012, Oncol Lett). Aerosolized CpG-ODN alone or 
Poly(I:C) alone failed to increase the percentage of NK cells in lung (Sfondrini L, 2013, Int J 
Cancer), while the combination of Poly(I:C)/CpG-ODN induced the expansion of NK cells, as 
showed by flow cytofluorimetric analysis of tumor infiltrating immune cells in lungs of mice i.v. 
injected with B16 melanoma cells and treated with aerosolized combined CpG-ODN/Poly(I:C) or 
with each agonist alone (figure 11.) (Mean % DX5+CD3-/CD45+ ± S.D.: 22.8 ± 1.5 % in 
untreated; 23.9 ± 2.5 % in CpG-ODN-treated; 25.5 ± 1.6 in Poly(I:C)-treated; 32.7 ± 2.1% in 
CpG-ODN/Poly(I:C)-treated; 4 mice/group; p=0.036 CpG-ODN/Poly(I:C) versus CpG-ODN; 
p=0.0094 CpG-ODN/Poly(I:C) versus untreated). 
Figure 11. 
Representative dot plots of NK cells (DX5+ cells gated on FSClowSSClowCD45+CD3- cells) obtained by enzymatic 
digestion of B16 metastases-bearing lungs of mice (4 mice/group) treated with aerosol CpG-ODN, Poly(I:C), CpG-
ODN/Poly(I:C) or left untreated. 
 
Analysis of the percentage of CD3 T lymphocyte did not reveal any expansion of these cells in 
lung of mice treated with aerosolized combined CpG-ODN/Poly(I:C) (Mean % CD3+/CD45+ ± 
S.D.: 19.96 ± 1.30 % in untreated; 16.76 ± 2.27% in CpG-ODN/Poly(I:C)-treated; 4 mice/group) 
These results suggest that the association of two TLR agonist administered by aerosol into the 
bronchoalveolar space is able to reduce the percentage of macrophages with M2 phenotype in B16 
tumor bearing lungs allowing an increase of tumor infiltrating NK cells.  
Since the combined treatment with the two TLR ligands might lead inflammation in lung 
parenchima, histopathological examination of hematoxylin and eosin-stained sections of lung 
tissues was performed to evaluate the possible toxic effect of repeated combined treatment with 
Poly(I:C)/CpG-ODN aerosol. Analysis on healthy mice treated twice weekly with Poly(I:C)/CpG-
ODN for 3 weeks showed focal areas of mononuclear and granulocytic infiltrate of the 
interstitium and absence of damage of bronchial-bronchiolar structures and of the alveolar walls in 
all lungs of mice treated with TLR3 and TLR9 agonists. Moreover, no overt signs of toxicity, such 
as weight loss, hunching, ruffled fur or difficulty breathing were observed (figure 12). 
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Figure 12. 
Histopathological evaluation of 
hematoxylin and eosin-stained lung 
tissue sections from aerosolized CpG-
ODN, Poly(I:C), or CpG-ODN/Poly(I:C) 
mice and untreated mice (magnification 
X400). 
 
2. Improved antitumor efficacy of CpG-ODN aerosol against B16 
experimental lung metastases through the association of aerosolized 
Poly(I:C) 
Thus, to evaluate a possible cooperative effect on antitumor activity of the two agonists 
simultaneously administered, compared to antitumor effect of treatment with each agonist alone, 3 
groups of mice were i.v. injected with B16 melanoma cells and treated twice weekly for 3 weeks 
starting 4 days after tumor injection. A fourth group of mice injected with tumor cells was left 
untreated and used as control. At 3 wk after tumor injection, the number of lung colonies was 
significantly lower in mice treated with both aerosolized CpG-ODN and Poly(I:C), as compared to 
mice treated with each aerosolized ligand alone (**p≤0.001 CpG-ODN/Poly(I:C) vs CpG-ODN; 
*p≤0.05 CpG-ODN/Poly(I:C) vs Poly(I:C)) (figure 13). 
 
 
 
 
 
 
 
 
Figure 13. 
A) Number of macroscopic lung metastases after i.v. 
injection of B16 melanoma cells in mice untreated (7 
mice) or treated with CpG-ODN aerosol (12 mice), 
Poly(I:C) aerosol (12 mice) or CpG-ODN/Poly(I:C) 
aerosol (14 mice) * p <0.05; *** p <0.001. 
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Therefore, our data show that the association of Poly(I:C) to CpG-ODN locally administered 
increase the antitumor activity of aerosolized CpG-ODN against B16 experimental lung 
metastases, without apparent signs of toxicity. 
 
3. Combination of dacarbazine increase the anti-tumor activity of CpG-
ODN/Poly(I:C) aerosolization in mice bearing B16 lung metastases  
Dacarbazine (DTIC) is an alkylating agent currently used in patients with metastatic melanoma. 
This chemotherapeutic agent is able to enhance the expression of NKG2D ligands on tumor cells, 
favouring NK cells activity (Hervieu A, 2013, J Invest Dermatol). Since antitumor activity of TLR 
agonists against B16 tumor is mostly mediated by NK cells, so it is possible to suppose that DTIC 
could increase antitumor activity of CpG-ODN/Poly(I:C) aerosol treatment. 
The DTIC-induced up-modulation of NKG2D ligands on B16 tumor cells was confirmed by 
cytofluorimetric analysis that revealed upregulation of Rae1 and Mult1 (figure 14a) after in vitro 
treatment of B16 melanoma cells with dacarbazine. Moreover, Real Time PCR analysis of 
NKG2D ligands in mRNA derivated from lungs of mice bearing experimental metastases of B16 
melanoma cells showed that in vivo treatment for 3 weeks with DTIC (80 mg/kg administered i.p. 
5 days/wk) induced an increase of Rae1 and Mult1 (figure 14b). 
 
 
 
 
 
 
 
 
 
Figure 14. 
A) MULT1 and RAE1 expression on the cell surface of B16 melanoma cells analyzed by flow cytometry after 24-h 
culture in complete medium alone (PBS) or supplemented with dacarbazine (DTIC) at different concentrations. The 
mean fluorescence intensity (MFI) was normalized to the isotype control. One representative experiment of 2 conducted 
is shown. B) Increase in Mult1 and Rae1 mRNA expression in lungs of mice injected i.v. with B16 melanoma cells and 
untreated or treated for 3 weeks with DTIC (80 mg/kg administered i.p. 5 days/week) (3 mice/group). Data represent 
mean relative expression (normalized to GAPDH) ± S.D. from 3 independent real-time PCR analyses.  ***p <0.001. 
 
Thus, we have evaluated the efficacy of the combination of DTIC to aerosol therapy with the two 
TLRs ligands in countering the growth of B16 lung metastases. To this aim, we performed two 
different experiments, starting treatment 4 or 7 days after tumor injection, to determine the activity 
of this combination administered at an early or more advantage stage of tumor growth, 
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respectively. In both experiments, mice were injected i.v. with B16 melanoma cells and divided 
into 4 groups. Three groups were treated with dacarbazine alone (80 mg/kg administered i.p. 5 
days/wk), or with Poly(I:C) and CpG-ODN aerosolization alone (15 mg and 1.5 mg respectively 
twice weekly), or with dacarbazine combined to Poly(I:C)/CpG-ODN aerosolization. A fourth 
group of mice injected with tumor cells was left untreated and used as control. 
Experiment in which the results of treatment was started 4 days after tumor injection revealed a 
significant reduction in the number of lung metastases 3 wks after tumor injection in mice 
receiving dacarbazine or Poly(I:C)/CpG-ODN aerosolization alone, as compared to untreated 
mice. However, the combination of Poly(I:C)/CpG-ODN aerosol with dacarbazine resulted more 
efficacious, as compared to Poly(I:C)/CpG-ODN aerosol or dacarbazine alone, and this 
combination resulted in 3 out of 8 mice completely cured at the end of the experiment (figure 
15a). 
Also in the experiment conducted treating mice one week after tumor injection, the aerosolized 
CpG-ODN/Poly(I:C) significant increased antitumor activity of dacarbazine (Mean number of 
lung metastases ± S.D.: Untreated mice 23.9 ± 7.3; Dacarbazine-treated mice 7.9 ± 3.8; 
Dacarbazine plus CpG-ODN/Poly(I:C) aerosol-treated 4.0 ± 3.1; p = 0.018 by t Student’s test 
Dacarbazine plus CpG-ODN/Poly(I:C) versus Dacarbazine alone) (figure. 15b). 
Figure 15. 
Number of macroscopic B16 melanoma lung metastases in mice untreated (7 mice) or treated with aerosol CpG-
ODN/Poly(I:C) (8 mice), DTIC (8 mice), or aerosol CpG-ODN/Poly(I:C) plus DTIC (8 mice) starting 4 days after 
tumor injection (A), and in mice untreated (7 mice) or treated with aerosol CpG-ODN/Poly(I:C) (8 mice), DTIC (7 
mice), or aerosol CpG-ODN/Poly(I:C) plus DTIC (16 mice) starting 1 week after tumor injection (B). *p <0.05; ** 
p<0.01 ***p <0.001. 
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4. Treatment with CpG-ODN/Poly(I:C) aerosol in combination with 
dacarbazine increases NK cells recruitment and activity against B16 
lungs metastases bearing mice 
We next evaluated whether the improved anti-tumor activity induced by combination of DTIC 
with aerosolized CpG-ODN/Poly(I:C) correspond to an increased immune activation. Mice were 
i.v. injected with B16 melanoma cells and treated with Poly(I:C)/CpG-ODN aerosolization alone, 
or with dacarbazine alone, or with dacarbazine combined to Poly(I:C)/CpG-ODN aerosolization, 
as above. After two weeks of treatment, no significant difference was observed in the percentage 
of immune infiltrate detected as CD45+ cells in lung suspensions obtained from mice of the 
different groups. CpG-ODN/Poly(I:C) aerosol treatment induced a significant increase of the 
frequency of NK cells (CD49+CD3-), as compared to untreated mice; a stronger increase in the 
percentage of NK cells was observed in mice treated with dacarbazine combined to aerosolized 
CpG-ODN/Poly(I:C), as compared to treatments with CpG-ODN/Poly(I:C) or dacarbazine alone 
(figure 16a). Combination of DTIC with CpG-ODN/Poly(I:C) aerosol also induced the highest 
expression of the activation marker CD69 on NK cells surface (figure 16b). Even if not 
significant, NK cells obtained from lungs of mice treated with this combination also showed a 
trend increase in the level of NKG2D expression, the activating receptor essential in NK-mediated 
elimination of tumor cells (figure 16c) (Zhang C, 2008, Hum Immunol). 
We then analyze whether the increased percentage and maturation of NK cells induced by 
combined treatment of DTIC and CpG-ODN/Poly(I:C) aerosol correspond to an increased NK 
cells cytotoxic activity against B16 tumor cells by a degranulation assay. Four groups of mice 
were injected i.v. with B16 melanoma cells and treated as above; after two weeks of treatments, 
suspension of cells obtained by enzymatic digestion of lung tissue were 24-hour co-cultured with 
B16 melanoma cells. An increase in the percentage of degranulating NK cells was induced by 
CpG-ODN/Poly(I:C) aerosol or by dacarbazin alone, but, the highest percentage of degranulating 
NK cells was observed in suspensions obtained from lungs of mice treated with the combination 
of CpG-ODN/Poly(I:C) aerosol and dacarbazin (Increase of the percentage of degranulating NK 
cells versus untreated: 2.4 fold in CpG-ODN/Poly(I:C) + DTIC, 1.8 fold in CpG-ODN/Poly(I:C) 
and 1.5 fold in DTIC) (figure 16d).  
Moreover, accordingly to data obtained in degranulation assay, evaluation of cytotoxic activity of 
lung immune cells from mice untreated or treated as above, against CFSE-labelled B16 target 
cells revealed a significant increase in the percentage of dead B16 cells after co-culture with lung 
suspensions from mice treated with combination of DTIC with CpG-ODN/Poly(I:C) 
aerosol(p=0.028) (figure 16e). 
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Altogether these results demonstrate that dacarbazine, through its ability to up-regulate NKG2DL 
on cancer cells, increases the anti-tumor activity of the two aerosolized TLR agonists, enhancing 
the cytotoxic activity of NK cells. 
Figure 16. 
Percentage and representative dot plots of NK cells (DX5+ cells gated on FSClowSSClowCD45+CD3- cells) (A), and 
of CD69+ (B) and NKG2D+ (C) NK cells, gated on DX5+ cells, obtained by enzymatic digestion of B16 metastases-
bearing lungs of mice (4 mice/group) treated with aerosol CpG-ODN/Poly(I:C), DTIC, aerosol CpG-ODN/Poly(I:C) 
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plus DTIC or left untreated.  Percentage and representative dot plots of degranulating NK cells (CD107a+ cells gated 
on CD45+CD3-DX5+ cells), after co-culture with B16 melanoma cells (D), and of CFSE-labeled B16 dead cells 
(7AAD+ cells gated on CFSE+ cells) after co-culture with cells obtained from lung enzymatic digestion (E). *p<0.05, 
***p <0.001. 
 
5. CpG-ODN/Poly(I:C)-activated lung macrophages stimulate NK cells 
cytotoxicity  
Our data demonstrated that aerosolized CpG-ODN/Poly(I:C) induced a strong anti-tumor effect 
related to stimulation of NK cells activity. Experiments were then performed to investigate the 
mechanism by which the two combined agonists could induce the activation of this effector cells 
populations. Although NK cells have been recently reported to express some TLRs, able to sense 
viral or bacterial PAMPs, controversies remain regarding a direct responsiveness of NK cells to 
these agonists (Adib-Conquy M, 2014, Immunol Cell Biol). Since different studies have suggested 
an involvement of macrophages in the activation of NK cells induced by TLR agonists. (Zhou Z, 
2012, PloS One; Nedvetzki S, 2007, Blood) Recently, the complex network of interaction between 
NK cells and polarized M1 that promotes NK cells activation has been recently demonstrated by 
in vitro experiments in human setting (Mattiola I, 2015, J Immunol). We therefore evaluate 
whether NK cells activation by combination of CpG-ODN/Poly(I:C) was induce by a direct 
stimulation or require macrophage activity. 
 
To assess whether association of two TLR agonists was able to directly induce IFN-γ secretion 
and NK cells cytotoxicity, purified splenic NK cells were in vitro stimulated with CpG-
ODN/Poly(I:C). Twenty-four hours after, a strong secretion of IFN-γ was observed, while no 
cytotoxic activity against YAC-1 cells was observed (figure 17). 
 
 
 
 
Figure 17. 
IFN-γ levels evaluated by ELISA in 
supernatant of NK cells pre-incubated with 
combined CpG-ODN/Poly(I:C) for 24 hrs. 
Percent specific lysis of YAC-1 target cells 
by purified splenic naïve NK cells pre-
incubated with combined CpG-
ODN/Poly(I:C) for 24 hrs. Box and 
whiskers: min to max. 
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To evaluate whether activation of NK cells cytotoxicity by aerosolized CpG-ODN/Poly(I:C) in the 
lung might be promoted by activation of resident macrophages, AMs obtained from 
bronchoalveolar lavages of healthy mice were pre-treated or not with two agonists. After 24 hr, 
pre-treated lung macrophages were extensively washed to completely remove TLR agonists or not 
washed and co-cultured with purified splenic NK cells. Co-culture of NK cells with TLR agonists-
pretreated lung macrophages significantly increased the percentage of lysis of YAC-1 cells, as 
compared to NK cells co-cultured with untreated lung macrophages (figure 18), even when 
macrophages were washed to remove TLR agonists, suggesting that activation of NK cells was 
mediated by signals induced by TLR agonists on macrophages. 
 
 
 
 
 
 
 
 
 
Figure 18. 
Percent specific lysis of YAC-1 target cells by purified splenic 
naïve NK cells cultured for 24 hr with alveolar macrophage pre-
incubated with combined CpG-ODN/Poly(I:C) for 24 hrs. Box and 
whiskers: min to max. *p ≤0.05; *p ≤0.01 
 
Consistent with a previous study published by Tross et al (Tross D, 2009, Mol Immunol) who 
investigated the genes expressed by RAW264.7 macrophage cell line in response to stimulation 
with combined CpG-DNA plus Poly(I:C), alveolar macrophages treated for 24 hrs with TLR 
agonists significantly increased expression of IL-6, IL-12 and IL-33 (figure 19). These in vitro 
results suggest that the stimulatory effect of TLR agonists on splenic NK cell cytotoxicity depend 
on activation of lung-derived macrophages induced by TLR agonists. 
 
Figure 19. 
Increased IL6, IL12 and IL33 mRNA 
expression in alveolar macrophage in 
vitro treated for 24 hrs with CpG-
ODN/Poly(I:C) Data are presented as 
2-ΔCt and represent mean relative 
expression ± SEM. from real-time PCR 
analyses. *p ≤0.05, ***p ≤0.001. 
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6. Crosstalk between CpG-ODN/Poly(I:C)-activated macrophages and 
NK cells in B16 melanoma tumor-bearing lung 
To evaluate whether this is a physiological mechanism working to activate NK cells in lungs of 
tumor bearing mice treated with aerosolized TLR agonists, two groups of C57BL/6 mice were i.v. 
injected with B16 melanoma cells and treated at 72 hr-interval starting from day 7 with CpG-
ODN/Poly(I:C), or left untreated. Three weeks after tumor injection, tumor infiltrating cells were 
obtained by enzymatic digestion of lungs, lung suspensions were then plated 2 hr at 37 °C to 
separate adherent cells, containing macrophages, from non-adherent cells, containing effector 
cells and then were analyzed by flow cytometry. Accordingly to our previous data, flow cytometry 
analysis revealed that TLR agonists induced an increased recruitment of NK cells in lungs, while 
no difference was detectable in the percentage of CD3 T cells (figure. 20). 
 
 
 
 
Figure 20. 
Percentage (±SEM) of NK cell, evaluated as 
CD49b+ cells gated on CD45+ cells, and 
Lymphocyte T, evaluate as CD3+ cells gated 
on CD45+ cell, in lung of B16 bearing mice 
treated with aerosolized CpG-ODN/Poly(I:C) 
or untreated. P* ≤0.05  
 
Cytotoxic assay perfomed using non-adherent cells were cultured with 51Cr-labelled YAC target 
cells revealed a significant increase in the percentage of lysis using lung suspension from mice 
treated with two agonists as compared to untreated mice, confirming the in vivo activation of NK 
cells by aerosol treatment with CpG-ODN/Poly(I:C) (figure. 21). 
 
 
 
 
 
 
 
Figure. 21 
Percent specific lysis of YAC-1 target cells by non-adherent cells 
from lung infiltrate of untreated mice or CpG-ODN/Poly(I:C) 
treated mice. Box and whiskers: min to max. 
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To assess whether macrophages derived from lung of mice aerosolized with TLR agonists were 
able to activate NK cell cytotoxicity, adherent cells were cultured for 24 hr with naïve NK cells, 
purified from spleen of C57BL/6 mice and then their cytotoxic activity assessed by 
51
Cr-release 
assay on YAC-1 target cells. A significant increase in the percentage of lysis was observed in 
naïve NK cells cultured with adherent cells from lungs of mice treated with TLR agonists, as 
compared to cells co-cultured with adherent cells from untreated mice (figure 22).  
 
 
 
 
 
 
 
Figure 22. 
Percent specific lysis of YAC-1 target cells by 
purified splenic naïve NK cells cultured for 24 hr 
with adherent cells from lung infiltrate of un treated 
mice or CpG-ODN/Poly(I:C) treated mice. Box and 
whiskers: min to max. *p ≤0.05 
 
Since a bidirectional crosstalk between NK cells and macrophages has been recently demonstrated 
by Mattiola et al. (Mattiola I, 2015, J Immunol), the ability of macrophages-activated NK cells to 
reciprocally influence macrophages polarization was assessed, incubating for 24 hr non-adherent 
cells from lungs of CpG-ODN/Poly(I:C) treated or untreated mice with naïve macrophages-
containing adherent cells from lavages of C57BL/6 healthy mice. As reported in figure 23, real 
Time PCR analysis on RNA extracted from macrophages incubated with non-adherent cells from 
lungs of CpG-ODN/Poly(I:C) treated mice revealed a significant up-regulation of M1 markers 
(IL-12, IL-6, iNOS2) and reduction of M2 related genes (IL-10, Arg1, IRF4, Alox15, STAT6) as 
compared to macrophages incubated with non-adherent cells from lungs of untreated mice. 
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Figure 23 
IL12, IL10, ARG1, NOS2, IRF4, IRF5, ALOX15, IL6, STAT1 and STAT6 mRNA expression in naïve alveolar 
macrophage incubated for 24 hrs with non-adherent cells from lung infiltrate of untreated mice or CpG-ODN/Poly(I:C) 
treated mice. Data are presented as 2-ΔCt and represent mean relative expression ± SEM. from real-time PCR analyses. 
*p ≤0.05, **p ≤0.01. 
 
Accordingly to the results obtained by Real Time PCR analysis, in the supernatants of naïve 
macrophages co-cultured with non-adherent cells from B16-bearing lungs of mice treated with 
CpG-ODN/Poly(I:C) a reduced secretion of IL-10 and an increased release of IL-12 and IL-6, as 
compared to macrophages co-cultured with cells from untreated mice was observed (figure. 24). 
Figure 24. 
IL12, IL10 and IL6 levels evaluated by Elisa in supernatant of naïve Alveolar macrophage incubated with non-adherent 
cells from lung infiltrate of untreated mice or CpG-ODN/Poly(I:C) treated mice. *p ≤0.05, ***p ≤0.001 
 
Taken together, our results demonstrate that aerosolization with CpG-ODN/Poly(I:C) induce in 
the lung the activation of macrophages, which in turn promote NK cells cytotoxicity. Moreover, 
our data suggest that activated NK cells in the lung have the potential to increase the macrophage 
programming to M1-like phenotype. 
 52 
 
We then focused our studies in the development of strategies to locally shape a lung 
microenvironment that further could favor macrophages-mediated NK cells activation against B16 
melanoma lung metastases, by combined inhalation-based immunotherapies. 
 
7. Increases CpG-ODN/Poly(I:C)-induced NK cells activity depleting 
locally MDSC by nebulized RB6-8C5 antibody 
B16 murine melanoma has been reported to strongly lead to the recruitment of MDSC in tumor 
microenvironment (Sceneay J, 2012, Cancer Res; Schlecker E, 2012, J Immunol; Youn J, 2008, J 
Immunol). Several studies showed a suppressive activity of MDSC on NK cells mainly through 
cell-cell contact mechanisms involving membrane-bound TGF-beta and recognition of NKG2D, 
activatory receptor of NK cells (Elkabets M, 2010, Eur J Immunol; Hoechst B, 2009, Hepatology; 
Li H, 2009, J Immunol; Liu C, 2007, Blood). Moreover, since a cross-talk between MDSCs and 
macrophages through soluble mediators and cell contact has been demonstrated to exacerbate a 
M2 phenotype shift of macrophages, resulting in increased IL10 production, reduction of IL12 
and IL6 production and increased immunosuppressive activity (Ostrand-Rosenberg S, 2012, 
Semin Cancer Biol) is possible that the presence of MDSCs on lung microenvironment hinder the 
macrophages activation by TLR agonist. 
Thus, in order to increase NK cells activation by aerosolized TLR agonists, creating a more 
permissive microenvironment, we assess the possibility to deplete MDSCs in the lung by 
nebulized RB6-8C5 antibody. C57BL/6 mice were i.v. injected with B16 melanoma cells and 
treated 7 days later with RB6-8C5 antibody or saline at 72-hr intervals. Cytofluorimetric analysis 
of enzymatically digested lungs revealed that nebulized RB6-8C5 antibody was able to reach the 
lung and significantly deplete both granulocytic (Ly6G
high
Ly6C
low
 cells) and monocytic MDSC 
(Ly6G
low
Ly6C
high
 cells) (Figure. 25). 
 
 
 
 
Figure 25. 
Representative dot plots and percentage (± SEM) of 
MDSC, identified as granulocytic 
(Ly6GhighLy6Clow) and monocytic (Ly6GlowLy6Chigh) 
MDSC (gated on CD11b+ cells among CD45+ 
cells) obtained by enzymatic digestion of lungs of 
mice injected i.v. with B16 melanoma cells and 
treated 7 days later with nebulized saline or RB6-
8C5 antibody (25 μg) (3 mice/group) at 72-hr 
intervals for 2 weeks *p≤0.05, ***p≤0.001.  
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Moreover, since our experiments revealed that granulocytic and monocytic MDSC repopulate 
completely the lungs at 96 hr after RB6-8C3 nebulization (Ly6G+Ly6Clow cells ± SEM: 57.1 ± 
8.3% in treated versus 56.4 ± 1.7% in untreated; Ly6GlowLy6C+ cells ± SEM: 3.6 ± 0.8% in 
treated versus 4.2 ± 0.3% in untreated; 2 mice/group), thus to maintain a prolonged depletion 
of these cells, we decided to repeat nebulized RB6-8C3 treatments at 72-96 hr intervals.  
 
The effect of MDSC depletion on recruitment and activation of NK cells induced by CpG-
ODN/Poly(I:C) aerosolization was evaluated in mice i.v. injected with B16 cells and treated with 
aerosolized CpG-ODN/Poly(I:C) alone or combined with nebulized RB6-8C5 antibody, as above 
described. Flow cytometry analysis of enzymatically digested lungs revealed that depletion of 
MDSC allowed an enhanced expression of CD69 activation marker on NK cells, without an 
increase in the recruitment of these cells (figure 28A). 
Although RB6-8C5 antibody is not only MDSCs specific, but can also target other Ly6G- or 
Ly6C-expressing cells, no significant difference in the frequency of macrophages, DCs, 
monocytes and T lymphocytes was detectable in lung of mice treated with aerosolized CpG-
ODN/Poly(I:C) and RB6-8C5 antibody compared to mice treated with TLR agonists alone (figure 
26). 
Figure 26. 
Percentage (± SEM) of macrophages (CD11b+CD11c+F4/80+ and CD11b+CD11c-F4/80+), dendritic cells 
(CD11b+CD11c+F4/80-), monocytes (CD11b+CD11c-F4/80-Ly6C+), CD8+ (CD3+CD8+) and CD4+ (CD3+CD4+) 
T lymphocytes in lung of mice i.v. injected with B16 melanoma cells and treated, starting 1 week later for 2 weeks at 72-
hr intervals, with aerosolized CpG-ODN/Poly(I:C) alone or combined with RB6-8C5 (25 μg). Three weeks after tumor 
injection lung were processed for flow cytometric analysis (4-5 mice/group). 
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Experiments were then performed to evaluate the effect of MDSC depletion on the expression of 
immunosuppressive marker in the lung. A strong reduction in expression of immunosuppressive 
markers strongly associated with MDSC suppressive activity (Keskinov A, 2015, Immunobiology) 
was observed in lungs of mice bearing B16 melanoma lung metastases treated with combined 
RB6-85 and CpG-ODN/Poly(I:C) aerosol, compared to mice treated with CpG-ODN/Poly(I:C) 
alone; as showed by analysis of Il-10, Arg-1 and Nos transcript levels in immune infiltrates 
obtained from lungs enzymatically digested (figure. 28B). 
Since we observed that macrophages are essential for activation of NK cell cytotoxicity also in the 
lung and their central role in responding to stimulation with TLR ligands, we assess whether 
MDSC depletion might increase the ability of CpG-ODN/Poly(I:C)-activated macrophages to 
promote the cytotoxic activity of NK cells. Mice were i.v. injected with B16 tumor cells and 
treated with aerosolized CpG-ODN/Poly(I:C) alone, or combined with nebulized RB6-8C5 
antibody, or with RB6-8C5 antibody alone, or left untreated. Three weeks after tumor cells 
injection, lung suspensions obtained from enzymatic digestion were plated 2 hr at 37 °C to 
separate adherent cells, containing macrophages, from non-adherent cells, containing effector 
cells. Adherent cells were then cultured with splenic naïve NK cells obtained from healthy mice 
and 24 hr later cytotoxic activity of NK cells was assessed on YAC target cells. In vivo 
combination of nebulized RB6-8C5 to TLR agonists significantly increased the ability of lung-
derived immune adherent cells to activate NK cell cytotoxicity (figure. 28C), increasing the 
stimulatory effect of CpG-ODN/Poly(I:C). No increase of NK cell cytotoxic activity was induced 
by treatment with RB6-8C5 antibody alone, suggesting that depletion of MDSC alone is not 
enough to promote macrophage-mediated NK cell activation. 
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Figure 28. 
A) Representative dot plots and percentage (± SEM) of NK cells (CD49b+ cells gated on FSClowSSClowCD45+CD3- 
cells); of CD69+ NK cells (gated on CD49b+ cells) and NKG2D+ NK cells (gated on CD49b cells), in mice untreated 
or treated with CpG-ODN/Poly(I:C) alone or combined with nebulized RB6-8C5 antibody (5 mice/group). **p≤0.01, 
***p≤0.001. B) mRNA levels (mean relative expression ± SEM) of IL10, Arg-1 and NOS2 evaluated by real-time PCR 
in mice treated with CpG-ODN/Poly(I:C) alone or combined with nebulized RB6-8C5 antibody from 2 independent 
experiments (4 mice/group in each experiment). Results are presented as 2-ΔCt; *p≤0.05. C) Percent specific lysis of 
YAC-1 target cells by purified splenic naïve NK cells cultured for 24 hr with adherent cells obtained by plating lung 
suspensions from mice untreated or treated with CpG-ODN/Poly(I:C) alone or combined with nebulized RB6-8C5 
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antibody or with RB6-8C5 antibody alone. Box and whiskers: min to max represent data pooled from 2 independent 
experiments (3-4 mice/group).  *p≤0.05; **p≤0.01. 
 
Altogether, these results indicate that airway delivered RB6-8C5 antibody reaches the 
bronchoalveolar space, efficiently depletes MDSC from the tumor microenvironment and this 
depletion allowed an increased NK cell activation by aerosolized CpG-ODN/Poly(I:C). Then, 
with the aim to directly promote effector cells activation, we assessed another inhalation-based 
immunotherapy using TLR agonists combined with aerosolized IFNα, essential for NK cell 
priming in response to cancer (Trinchieri G, 1978, J Exp Med; Karimi K, 2015, Innate Immun) 
and able to induce the M2 to M1 phenotypic shift in the lung microenvironment (Zhuang PY, 
2013, PloS One). 
 
8. NK cell activation in lung by aerosolized IFN-α 
IFN-I are essential elements for priming and activation of NK cells, since its ability to enhance 
their cytotoxicity and IFN-γ production. IFN-I also represent the principal inducers of IL-15 
production, essential for NK cells accumulation and survival. In addition to its direct effects on 
NK cells, IFN-α is known to stimulate other cell types critical for NK effector activation, such as 
macrophages and DC, and to promote a shift of macrophages to tumoricidal effectors (Zhuang PY, 
2013, PloS One). We therefore evaluate the possibility to deliver IFN-α to the lung by 
aerosolization, as strategy to increase its concentration locally and limit the possible toxicity 
associated with systemic administration (Trinchieri G, 2010, J Exp Med) and to improve immune 
activation in the lung induced by aerosol CpG-ODN/Poly(I:C). Healthy mice were treated at 
intervals of 72 hrs with aerosolized IFN-α for 2 wk. Flow cytometry analysis of immune cells 
obtained from enzymatic digestion of lungs showed a significant increase in the percentage of NK 
cells and up-modulation of CD69 and NKG2D activation markers on their cell surface, as 
compared to untreated mice (figure. 29A). Moreover, an increased expression of IL-15Ra was 
also observed on NK cells surface (figure. 29A) and in RNA extracted from lung immune 
infiltrates of IFN-α-treated mice (figure. 29B). Analysis of transcript levels in RNA extracted 
from lung immune infiltrates of these mice also revealed a significant up-regulation of IL-15 and 
IFN-γ (figure. 29B). 
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Figure 29. 
A) Percentage (± SEM) of NK cells evaluated by flow cytometry as CD49b+ cells gated on FSClowSSClowCD45+CD3- 
cells, of CD69+ NK cells gated on CD49b+ cells; NKG2D+ NK cells gated on CD49b cells and IL-15Ra+ NK cells 
gated on CD49b+ cells in healthy mice untreated or treated with aerosolized IFNα at 72-hr intervals for 2 weeks (4 
mice/group); *p≤0.05. B) Percent (± SEM) IL15Ra, IL15 and IFNγ mRNA levels evaluated by real-time PCR and given 
as mean relative expression from 2 independent experiments (4 mice/group in each experiment). Results are presented 
as 2-ΔCt; *p≤0.05. C) Percent specific lysis of YAC-1 target cells by purified splenic naïve NK cells cultured for 24 hr 
with adherent cells obtained by plating lung suspensions from mice treated with CpG-ODN/Poly(I:C) alone or 
combined with aerosolized IFNα. Box and whiskers: min to max represent data obtained from 4 mice/group; *p≤0.05. 
 
Moreover, our experiments indicated that IFN-α aerosol therapy was well-tolerated, since mice 
did not reveal overt signs of toxicity, such as weight loss, hunching, ruffled fur or difficulty 
breathing. Furthermore, histopathological examination of hematoxylin and eosin-stained sections 
of lung tissue revealed no histological changes in the structure of lungs (figure. 30). 
Figure 30. 
Body weight and representative histopathological evaluation of hematoxylin and eosin-stained lung tissue sections from 
mice treated with aerosolized IFNα or saline (4 mice/group). No effects on body weight or lung histology were observed 
in mice exposed to IFNα aerosolization.  Magnification X200. 
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In a model of lung metastases induced by hepatocellular carcinoma cells, it was been reported that 
IFN-α promote macrophage anti-tumor activity through their shift to M-1 phenotype (Zhuang PY, 
2013, PloS One; Hervas-Stubbs S, 2011, Clin Cancer Res). Thus, we assessed whether association 
of IFN-α to CpG-ODN/Poly(I:C) aerosol therapy in mice bearing B16 melanoma metastases 
increases the ability of lung-derived macrophages to promote the cytotoxic activity of NK cells. 
Adherent cells obtained from lung suspensions of mice i.v. injected with B16 cells and treated 
with aerosolized IFN-α plus CpG-ODN/Poly(I:C) induced a significantly increased cytotoxic 
activity of naïve NK cells against YAC target cells as compared to adherent cells from lungs of 
mice treated with aerosolized CpG-ODN/Poly(I:C) alone (figure 29C). 
Together, these data show that aerosolized IFN-α reach the bronchoalveolar space in the lung and 
locally activate an innate immune response without apparent signs of toxicity, improving the 
macrophages-mediated activation of NK cells by aerosolized CpG-ODN/Poly(I:C). 
 
9. Anti-tumor efficacy of CpG-ODN/Poly(I:C) aerosol therapy improved 
by the association of Nebulized RB6-8C5 antibody and IFN-α 
aerosolization 
The local depletion of MDSC from lung microenvironment by RB6-8C5 nebulization and the 
local delivery of IFN-α has proved to be able to increase NK cells activation induced by CpG-
ODN/Poly(I:C) aerosol treatment. In order to evaluate which of the two combination, was more 
effective in increasing the anti-tumor effect induced by CpG-ODN/Poly(I:C) aerosolization in the 
treatment of B16 melanoma lung metastases, different combined treatments were started one week 
after i.v. injection of B16 tumor cells. At this time, indeed, the presence of multiple microscopic 
metastatic foci was clearly detectable in the lung (figure. 31A). 
B16 tumor bearing mice were divided in six groups and treated for 2 weeks at 72 hr interval with 
aerosolized CpG-ODN/Poly(I:C) alone or combined to RB6-8C5 or IFN-α, or with RB6-8C5 or 
IFN-α alone, or left untreated. Both combinations of CpG-ODN/Poly(I:C) aerosol with RB6-8C5 
or IFN-α induced a significant increase of antitumor activity, as compared to Poly(I:C)/CpG-ODN 
aerosol alone (figure 31B). No significant anti-tumor effect was observed by treatment with RB6-
8C5 or IFN-α alone. 
To investigate whether the observed reduction in the number of lung metastases was related to an 
increased ability of NK cells to promote anti-tumor activity, lungs were enzymatically digested 
and cytotoxic activity of non-adherent immune cells was evaluated using B16 tumor cells as 
target. The result of this experiment revealed a significant increase in the percentage of lysis by 
lung suspensions obtained from mice treated with CpG-ODN/Poly(I:C) combined to RB6-8C5 
antibody or IFN-α, as compared to those from mice treated with CpG-ODN/Poly(I:C) alone 
(figure. 31C). 
 59 
 
To assess a possible synergistic effect in combining CpG-ODN/Poly(I:C) aerosol with RB6-8C5 
nebulization and IFN-α aerosolization, an experiment was performed in mice i.v. injected with 
B16 melanoma cells and treated starting one week after tumor injection, as above, with 
aerosolized CpG-ODN/Poly(I:C) combined to RB6-8C5 or to IFN-α or to RB6-8C5 plus IFN-α. A 
control groups was left untreated. The results of this experiment confirmed the strong reduction in 
the number of lung metastases obtained combining CpG-ODN/Poly(I:C) with RB6-8C5 antibody 
or IFN-α, but no synergistic effect was observed in mice treated with CpG-ODN/Poly(I:C) 
combined to both reagents (Figure. 31D). 
Altogether, these results indicate that an immunotherapeutic strategy based on direct delivery in 
the lung of CpG-ODN/Poly(I:C) by aerosol combined with local nebulization of an antibody to 
deplete MDSC or with aerosolized IFN-α significantly increases the antitumor activity of the two 
TLR agonists, allowing an increased activation of anti-tumor effector cells. 
Figure 31 
A) Representative images of multiple metastatic foci in hematoxylin and eosin-stained lung tissue sections from mice at 
day 7 after i.v. injection of B16 melanoma cells. Magnification X200. B) Mean number of B16 melanoma lung 
metastases in mice injected i.v. with B16 melanoma cells and untreated (7 mice) or treated starting at day 7 at 72-hr 
intervals for 2 weeks with nebulized RB6-8C5 alone (6 mice), aerosolized IFN-α alone (6 mice), aerosolized CpG-
ODN/Poly(I:C) alone (8 mice), aerosolized CpG-ODN/Poly(I:C) combined with RB6-8C5 (8 mice) or IFNα aerosol (7 
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mice). *p≤0.05; ***p≤0.001. C) Percent specific lysis of B16 target cells by non-adherent cells obtained by plating 
suspensions of digested lungs from untreated or treated mice after 24 hr co-culture. Box and whiskers: min to max 
represent data pooled from 2 independent experiments (3-4 mice/group) *p≤0.05; **p≤0.01. D) Mean number of B16 
melanoma lung metastases in mice injected i.v. with B16 melanoma cells untreated (6 mice) or treated starting at day 7 
at 72-hr interval for 2 weeks with aerosolized CpG-ODN/Poly(I:C) combined with RB6-8C5 (9 mice) or with IFNα (9 
mice) or with RB6-8C5 and IFNα (9 mice). 
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DISCUSSION 
Locoregional therapy with drugs administered by aerosols represents an option for treating asthma 
and chronic obstructive pulmonary disease but could be a promising pathway to combat also 
metastatic lung tumors. Only a minority of patients with primary lung cancer are eligible for 
curative surgical resection. Similarly, surgical treatment of lung metastases is often 
contraindicated due to the number or site of the lesions and the patient’s respiratory and general 
status. Chemotherapy is therefore widely used in both primary and secondary lung carcinomas, 
but its clinical efficacy remains limited. Several studies have demonstrated that after systemic 
administration the drug concentration in lung tumors is low. Thus, the poor clinical outcome often 
observed in lung cancer patients has been partly attributed to the inability to achieve therapeutic 
concentrations at the tumor site (Sharma S, 2001, J Clin Oncol). Because bronchial and 
bronchoalveolar tumors are accessible via the endobronchial space, lung cancers are candidate 
tumors for taking advantage of local delivery. Inhalation of aerosolized drugs, allowing increased 
comfort to patients and self-administration, could be a convenient and simple approach for 
repeated application to treat primary lung cancer and to treat and/or prevent metastases derived 
from different types of primary tumors.  
Several therapeutic agents have been explored for inhalation delivery in malignancies, including 
chemotherapeutic agents (Lemarie E, 2011, J Aerosol Med Pulm Drug Deliv; Reed MD, 2013, Br 
J Cancer), cytokines (Esteban-Gonzalez E, 2007, Anticancer Drugs; Guma SR, 2014, Pediatr 
Blood Cancer), antisense oligonucleotides (Mainelis G, 2013, J Aerosol Med Pulm Drug Deliv), 
and monoclonal antibodies (Maillet A, 2011, Pharm Res), demonstrating the feasibility of aerosol 
delivery, the potential anti-tumor effects and the reduced side-effects compared to systemic 
treatment, allowing to reach with a higher local concentration of drugs. 
Previously studies of aerosol delivery of TLR9 agonist performed in the laboratory where I 
conducted my thesis showed that aerosolized CpG-ODN was able to reach the bronchoalveolar 
space, locally activate an immune response without any apparent signs of toxicity and was more 
efficacious than systemic administration against lung metastases of N202.1A mammary 
carcinoma cells. In contrast, aerosol delivery of CpG-ODN was not very effective against 
metastases of B16 melanoma cells, which selectively recruit CD68+ macrophages with an M2 
phenotype and induce an immunosuppressive environment that hinder the recruitment of NK cells 
(Sfondrini L, 2013, Int J Cancer). 
The first aim of this thesis was to explore the aerosol administration of Poly(I:C), reported able to 
convert TAMs to those with tumoricidal properties, for a possible combination with CpG-ODN to 
simultaneously reduce immunosuppressive microenvironment while activating tumor-infiltrating 
immune cells, as a novel approach for the treatment of lung metastases. Because lungs are in 
contact with the external environment, the airways are occupied by a significant population of 
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immunosuppressive cells to prevent continuous lung inflammation but, in the presence of cancer, 
they can support tumor growth. TAMs are one of the major immunosuppressive cells in the tumor 
microenvironment able to influence tumor progression and the success or failure of 
immunotherapy (Mantovani A, 2011, Eur J Immunol) and emerging evidences reveal a significant 
correlation between high TAM numbers and poor patient prognoses in NSCLC patients (Chung 
FT, 2012, Int J Cancer; Ohtaki Y, 2010, J Thorac Oncol; Zhang B, 2011, Clinics; Zeni E, 2007, 
Eur Respir J; Wang R, 2011, J Exp Clin Cancer Res). 
We highlighted that the addition of Poly(I:C) to aerosolized CpG-ODN resulted in increased anti-
tumor activity in mice bearing B16 lung metastases as compared to mice treated with either 
aerosolized TLR agonists alone. The enhanced anti-tumor effect of the CpG-ODN/Poly(I:C) 
aerosol combination correlated with a significant reduction in the number of macrophages 
producing arginase and/or IL-10 and/or CD163 expressing macrophages, three different markers 
of the M2 phenotype, which are selectively recruited by B16 melanoma cells in the lung and 
responsible for the low efficacy of locally delivered CpG-ODN alone (Sfondrini L, 2013, Int J 
Cancer). Moreover, our results showed that aerosolization of the two TLR agonists into the 
bronchoalveolar space did not induce evident signs of toxicity on mice and/or signs of injury in 
the architecture and structure of lung parenchyma. Other immune populations can contribute to 
the tumor-induced immunosuppressive microenvironment. Myeloid-derived suppressor cells 
(MDSC) represent one of the most relevant of these populations. Besides blocking conversion of 
tumor-associated macrophages to the M2 phenotype, Poly(I:C) treatment was shown to promote 
the maturation of myeloid-derived suppressive cells (MDSC), immature cells often elevated in 
tumor-bearing hosts, rendering them competent for NK cell activation (Shime H, 2014, J Innate 
Immun). Our results indicated that the combination of Poly(I:C) with aerosolized CpG-ODN 
significantly expanded the frequency of CD49b+ cells in lung tumor infiltrates and increased their 
cytotoxic activity against B16 tumor cells. Thus, activation of NK cells might depend on an effect 
of aerosolized CpG-ODN on NK cells promoted by both the blocking of suppressive macrophages 
by Poly(I:C), and also on the induction by Poly(I:C) of NK cell-activating molecules on MDSC 
present in the tumor microenvironment. 
Since a heightened immune response alone can rarely cure patients, in this thesis we also 
evaluated the combination of aerosolized CpG-ODN/Poly(I:C) with chemotherapy. Accumulating 
evidence indicates that some of them have immuno-therapeutic activities. Dacarbazine, for 
example, was recently shown to trigger the expression of NKG2D ligands on mouse tumor cells, 
thus indirectly promoting NK cell cytotoxicity (Ugurel S, 2013, J Invest Dermatol). Hervieu et al. 
(Hervieu A, 2013, J Invest Dermatol) demonstrated that coculture of different human NK cells 
with dacarbazine-treated human melanoma cell lines was shown to sensitize the melanoma cells to 
NK cell lysis and that the increase in mortality of tumour cells was prevented by addiction an anti-
human NKG2D antibody. Accordingly, our results indicated that treatment with dacarbazine up-
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modulated RAEI and MULTI expression in B16 melanoma cells both in vitro and in vivo, and 
that the combination of dacarbazine with aerosol CpG-ODN/Poly(I:C) induced a significant 
increase in the frequency and degranulation activity of CD49b+ cells, resulting in improved anti-
tumor activity. Note that the induction of NKG2D ligand expression has also been observed for 
other genotoxic agents, such as 5-fluorouracil and cisplatin (Gasser S, 2005, Nature; Khallouf H, 
2012, J Immunother), raising the possibility that other chemotherapeutic drugs might increase the 
anti-tumor activity of aerosol CpG-ODN/Poly(I:C). 
Overall the results obtained in the first part of this thesis revealed that repeated aerosol delivery of 
immunostimulants, such as TLR9 and TLR3 agonists, might represent a convenient and simple 
approach to locally maintain activation of NK cells, while inhibiting polarization of tumor-
infiltrating myeloid derived cells versus an immunosuppressive phenotype, minimizing their 
possible systemic side-effects. Moreover, this strategy might improve the response to standard 
treatments with chemotherapeutic agents by maintaining an immune microenvironment able to 
counteract tumor growth. 
In the second part of project we focused to investigate the mechanism by which the two combined 
agonists could induce the activation of effector cells, investigating the interplay between NK cells 
and alveolar macrophages. AMs, resident innate immune cells in the lungs and characterized by 
an M2-like phenotype, are critical in maintaining immune homeostasis, preventing unwanted 
reactions against antigens that are inhaled during the respiratory process (Hussell T, 2014, Nat Rev 
Immunol). These cells exert their immunomodulatory activity through the release of various 
factors, including PGE2, NO, and IL-10 (Bingisser RM, 2001, Swiss Med Wkly), or a cell-cell 
contact-dependent mechanism, switching off innate and adaptive immunity. 
However, alveolar macrophages are an important component of host defense against invading 
microorganisms, and it has been proposed that TLR engagement on these cells attenuates their 
immunosuppressive activity through the downmodulation of IL-10 receptor (Fernandez S, 2004, J 
Immunol). 
Consistent with several in vitro observations (Baratin M, 2005, PNAS; Bellora, 2014, Eur J 
Immunol; Eissmann P, 2010, J immunol; Tu Z, 2008 J Exp Med) our results support that alveolar 
macrophages are required to induce NK cell cytotoxicity stimulated by TLR agonists. The 
increased cytotoxicity of NK cells that is induced by TLR agonist-activated alveolar macrophages 
might be related to the secretion of soluble mediators by activated macrophages. Accordingly, we 
found that IL-6, IL-12 and IL-33 mRNA levels were raised in bronchoalveolar-derived adherent 
cells incubated for 24 hrs with TLR agonists. IL-12 (Bourgeois E, 2009, Eur J Immunol), a 
cytokine crucial in promoting NK cell cytotoxicity, has been indeed reported to synergize with IL-
33 to promote NK cell activation and IFN-γ production. Moreover, it has been also reported that 
transgenic expression of IL-33 increases NK cell cytotoxic activity in vitro and in vivo against 
B16 melanoma cancer cells (Gao X, 2015, J Immunol). 
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If macrophages govern NK cell behavior, the latter might influence macrophage biology. Notably, 
our ex vivo experiments using NK cells from the lungs of mice that harbored B16 metastases 
treated with aerosolized TLR agonists, demonstrated that these cells induced a shift toward an 
M1-like phenotype in naive alveolar macrophages. After being cocultured with activated NK 
cells, naive alveolar macrophages indeed up-regulated M1 markers, such as NOS2, and increased 
their secretion of M1 cytokines, as IL-12 and IL-6. Concurrently, a decline in M2-associated 
molecules, such as IRF4 and Alox15, and IL-10 secretion in macrophages was observed. 
Accordingly with data obtained by Mattiola et al. (Mattiola I, 2015, J Immunol), these results 
indicate that the crosstalk between NK cells and macrophages favors the reprogramming of 
macrophages toward the M1 phenotype, thus sustaining the antitumor response that is induced by 
TLR agonists. Thus, therapeutic approaches, such as the local administration of TLR9 and TLR3 
agonists, that re-educate tumor-associated macrophages toward the M1-like phenotype can also 
take exploit this positive feed-forward loop with NK cells to potentiate the antitumor M1 
phenotype.  
Therefore, the data yielded in the second part of this thesis has demonstrated that in the lung, NK 
cell activation by TLR agonists is mediated by macrophage activity. Given the increasingly 
appreciated function of NK cells in protective therapeutic strategies against cancer (Rezvani K, 
2015, Front Immunol), our findings contribute to establishing the sequence of immune cell 
activation that triggers NK cells in vivo by immunotherapeutic agents. 
The last aim of this thesis was to evaluate strategies to improve the efficacy of CpG-
OND/Poly(I:C) aerosolization against lung cancer by combination with other aerosolized 
immunotherapeutic agents, to favor a lung microenvironment more permissive to an effective 
immune destruction of tumors by NK effector. 
We evaluated the usefulness of RB6-8C5 nebulized antibody, to deplete MDSC cells and thereby 
create a more permissive microenvironment for NK cell activation by aerosolized TLR agonists 
(Saiwai H, 2013, J Neurochem). The feasibility of using nebulized therapeutic antibodies was 
demonstrated in a study showing that airway-delivered cetuximab, an anti-EGFR antibody, 
accumulated rapidly in cancerous lung tissue at concentrations twice those achieved after i.v. 
delivery (Guilleminault L, 2014, J Control Release) and in a study on an anti-influenza virus 
neutralizing MAb that revealed higher concentrations of the antibody in the bronchoalveolar 
lavage fluid (BAL), with low penetration into the bloodstream upon direct delivery to the 
respiratory tract (Leyva-Grado V, 2015, Antimicrob Agents Chemother). Moreover, local delivery 
of an anti-VEGF MAb to K-ras-induced adenocarcinoma-bearing lungs efficiently reduced tumor 
burden at ~100-fold lower serum concentration of MAb than that after systemic delivery (Herve 
V, 2014, MAbs) 
Airway-delivered RB6-8C5 antibody, directed to both Ly6G and Ly6C, at 72-96 hr interval 
effectively depleted MDSC recruited in the lung tumor microenvironment at a dose 4- to 8-fold 
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lower than that used in systemic administration (Saiwai H, 2013, J Neurochem; Srivastava M K, 
2012, PloS One), improving antitumor effects of aerosolized TLR agonists. Although RB6-8C5 
antibody is not only MSDCs specific, but can also target other Ly6G- or Ly6C-expressing cells, at 
a late time point of the experiment no differences in the percentage of macrophages, DCs, 
monocytes and CD8+ T cells were observed in the lungs. Our data indicate that while MDSC 
depletion by the nebulized antibody did not enhance NK cell recruitment induced by CpG-
ODN/Poly(I:C), depletion did lead to increased NK cell activation, possibly by minimizing direct 
inhibition of these effector cells and/or by enhancing the ability of aerosolized CpG-
ODN/Poly(I:C)-activated macrophages to promote NK cell cytotoxicity. Accordingly, Mattiola et 
al. (Mattiola I, 2015, J immunol) have demonstrated in vitro that LPS/IFNγ-polarized M1 
macrophages, but not M0 or IL4-polarized M2 macrophages, can prime resting autologous NK 
cells. Thus, the ex vivo results showed in this thesis indicating that nebulized RB6-8C5 combined 
with TLR agonists significantly increases the ability of lung-derived immune adherent cells to 
activate cytotoxicity of naïve NK cells suggest that MDSC depletion also favors reprogramming 
of macrophages to the M1 phenotype. Consistent with our results, systemic MDSC depletion by 
RB6-8C5 antibody in a model of murine Lewis lung carcinoma induced increased anti-tumor NK 
and T cell activity that was related to enhanced functional activity of antigen-presenting cells, 
such as macrophages and dendritic cells, in the tumor (Srivastava MK, 2012, PloS One). 
Moreover, we evaluated the possibility to directly increase the potency of NK cells, acting directly 
on these cells. To this aim we aerosolized CpG-ODN/Poly(I:C) together with IFNα, a 
proinflammatory cytokine has been used successfully to treat infections and several types of 
cancer, based on its ability to promote NK cell activation. For example, IFNα is used as an 
adjuvant therapy after surgery to prevent recurrence of melanoma, although side-effects upon 
systemic treatment are substantial (Jonasch E, 2001, Oncologist). Our results indicate that 
aerosol-delivered IFNα reaches lung NK cells, promotes their recruitment and activation, and 
upregulates IL15/IL-15Ra expression necessary for NK cell priming. Notably, we detected no 
evident signs of toxicity on the structure of lung parenchyma or on the weight and behavior of 
mice, consistent with data indicating that aerosol-delivered IFNα in patients with pulmonary 
tuberculosis reaches the lower respiratory tract without systemic side-effects (Giosue S, 2000, Eur 
Cytokine Netw).  
No significant anti-tumor effect was observed in mice treated with aerosolized IFNα alone, 
consistent with the limited anti-tumor effect reported in some pioneer studies in patients with 
advanced bronchioalveolar carcinoma treated with inhaled IFNα alone (Van Zandwijk N, 1990, 
Eur J Cancer; Kinnula V, 1990, Eur J Cancer). However, in combination with TLR9 and TLR3 
agonists, which strongly activate an innate immune response while reducing M2 polarization, 
IFNα improved NK-mediated protective immunity, raising the possibility that TLR agonists create 
a microenvironment favorable for immune stimulation by IFNα. Additive immunostimulatory 
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effects by IFNα and CpG-ODN were observed in an intraperitoneal model of melanoma 
systemically treated with IFN-α and CpG-ODN (Brown L, 2006, Surgery), and a synergistic effect 
of CpG-ODN and IFNα on dendritic cell maturation was found in mice bearing MC38 colorectal 
cancer treated with dendritic cells pre-incubated with IFNα-secreting cells and CpG-ODN 
(Hiraide A, 2008, Cancer Sci). In addition to its direct effects on NK cells, IFNα is known to 
stimulate other cell types critical for NK effector activation, such as macrophages and DC 
(Hervas-Stubbs S, 2011, Clin Cancer Res), and to promote a shift of macrophages to tumoricidal 
effectors, as shown in a model of lung metastases induced by hepatocellular carcinoma cells, 
wherein systemic IFNα treatment directly transformed the lung microenvironment by modulating 
macrophage polarization (Zhuang PY, 2013, PloS One). Accordingly, we found that adherent cells 
from lung immune infiltrates of B16 metastases-bearing mice treated with CpG-
ODN/Poly(I:C)/IFNα aerosol significantly increased cytotoxic activity of naïve NK cells, as 
compared to cells from mice treated with CpG-ODN/Poly(I:C) alone. 
The two different inhaled combinations showed a similar level of anti-tumor effect, i.e., up to 79% 
reduction in mean number of lung metastases. Unexpectedly, no additive effect was observed in 
mice treated with CpG-ODN/Poly(I:C) combined with both IFNα and MDSC-depleting antibody. 
Further experiments are needed to assess a possible interference between IFNα and the MDSC-
depleting antibody and to evaluate other doses or time frames of administration. 
Together, the results of this thesis indicate that an effective anti-tumor response can be obtained 
against established lung multiple foci of a highly aggressive tumor using airway delivery as a 
convenient and non-invasive way to administer immunotherapy. 
This proof-of-principle project of thesis points the promise of rational combinations of 
immunostimulants, cytokines and antibodies delivered locally by inhalation to reprogram the 
immune tumor microenvironment as a novel strategy to treat lung cancer patients. 
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